J. Fruchart

发表

Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As

S. Grundy, J. Cleeman, K. Donato, 2009, Circulation.

Niemann-Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine.

B. Staels, J. Fruchart, C. Duval, 2006, Biochemical and biophysical research communications.

Upregulation of the low density lipoprotein receptor at the blood-brain barrier: intercommunications between brain capillary endothelial cells and astrocytes

M. Dehouck, R. Cecchelli, J. Fruchart, 1987, The Journal of cell biology.

Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators

W. Koenig, J. Maclouf, A. Tedgui, 1998, Nature.

Peroxisome proliferator-activated receptors in inflammation control.

B. Staels, J. Fruchart, P. Delerive, 2001, The Journal of endocrinology.

PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases.

R. Bordet, D. Deplanque, B. Staels, 2006, Biochemical Society transactions.

Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors

B. Staels, J. Fruchart, P. Gervois, 2007, Nature Clinical Practice Endocrinology &Metabolism.

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.

A. Gotto, S. Grundy, P. Barter, 2007, The New England journal of medicine.

The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice*

Folkert Kuipers, A. Grefhorst, F. Gonzalez, 2006, Journal of Biological Chemistry.

Phosphorylation of farnesoid X receptor by protein kinase C promotes its transcriptional activity.

D. Hum, B. Staels, J. Fruchart, 2008, Molecular endocrinology.

Familial hypoalphalipoproteinemia in premature coronary artery disease.

J. Ordovás, E. Schaefer, J. Fruchart, 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1*

Frank J. Gonzalez, G. Haegeman, J. Peters, 1999, The Journal of Biological Chemistry.

Mechanism of action of fibrates on lipid and lipoprotein metabolism.

J Auwerx, B Staels, J. Auwerx, 1998, Circulation.

Abnormal reverse cholesterol transport in controlled type II diabetic patients. Studies on fasting and postprandial LpA-I particles.

J. Fruchart, N. Nicolaïew, E. Cavallero, 1995, Arteriosclerosis, thrombosis, and vascular biology.

Retinoic acid receptor-related orphan receptor alpha as a therapeutic target in the treatment of dyslipidemia and atherosclerosis.

J. Fruchart, Heidelinde Jakel, J. Fruchart-Najib, 2006, Drug news & perspectives.

Value of HDL Cholesterol, Apolipoprotein A-I, Lipoprotein A-I, and Lipoprotein A-I/A-II in Prediction of Coronary Heart Disease: The PRIME Study

A. Evans, D. Arveiler, G. Luc, 2002, Arteriosclerosis, thrombosis, and vascular biology.

Polymorphisms in the insulin response element of APOC-III gene promoter influence the correlation between insulin and triglycerides or triglyceride-rich lipoproteins in humans

P. Amouyel, D. Cottel, J. Dallongeville, 2000, International Journal of Obesity.

P. Amouyel, D. Cottel, J. Dallongeville, 2000, Atherosclerosis.

Relation of Arteriographically Defined Coronary Artery Disease to Serum Lipoprotein Particles Mapped With Monoclonal Antibodies

M. C. Nuttens, P. Ducimetiere, J. Fruchart, 1991, Circulation.

The use of monoclonal antibodies to localize the low density lipoprotein receptor-binding domain of apolipoprotein B.

E. Rassart, Y. Marcel, J. Scott, 1989, The Journal of biological chemistry.

3‐Hydroxy‐3‐methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C‐III and lipoprotein lipase

J. Auwerx, K. Schoonjans, J. Fruchart, 1999, FEBS letters.

Peroxisome proliferator‐activated receptor (PPAR) agonists decrease lipoprotein lipase secretion and glycated LDL uptake by human macrophages

B. Staels, G. Olivecrona, J. Fruchart, 2002, FEBS letters.

Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.

W. Koenig, J. Maclouf, A. Tedgui, 1998, Nature.

PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter.

J. Auwerx, L. Fajas, J. Fruchart, 1998, FEBS letters.

PPARa activators improve insulin sensitivity and reduce adiposity

L. Madsen, T. Willson, E. Raspé, 2000 .

Peroxisome Proliferator-activated Receptor α Activators Improve Insulin Sensitivity and Reduce Adiposity*

Bruno Derudas, Timothy M. Willson, L. Madsen, 2000, The Journal of Biological Chemistry.

PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance.

G. Reach, J. Peters, F. Gonzalez, 2001, Diabetes.

PPAR-α–Null Mice Are Protected From High-Fat Diet–Induced Insulin Resistance

G. Reach, J. Peters, F. Gonzalez, 2001 .

Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis.

B. Staels, J. Fruchart, G. Chinetti, 2006, The Journal of clinical investigation.

Drug Transfer Across the Blood‐Brain Barrier: Correlation Between In Vitro and In Vivo Models

J. Tillement, M. Dehouck, R. Cecchelli, 1992 .

In vitro reconstituted blood-brain barrier

M. Dehouck, R. Cecchelli, S. Méresse, 1992 .

Drug transfer across the blood-brain barrier: Correlation between “in vitro” and “in vivo” models

M. Dehouck, R. Cecchelli, J. Fruchart, 1992, Neurochemistry International.

Diabetes mellitus worsens antioxidant status in patients with chronic pancreatitis.

D. Quilliot, J. Bonte, J. Fruchart, 2005, The American journal of clinical nutrition.

Fatty acid abnormalities in chronic pancreatitis: effect of concomitant diabetes mellitus

D. Quilliot, P. Böhme, J. Bonte, 2003, European Journal of Clinical Nutrition.

Effect of the inflammation, chronic hyperglycemia, or malabsorption on the apolipoprotein A-IV concentration in type 1 diabetes mellitus and in diabetes secondary to chronic pancreatitis.

D. Quilliot, J. Fruchart, B. Guerci, 2001, Metabolism: clinical and experimental.

Liver X Receptor Activation Induces the Uptake of Cholesteryl Esters From High Density Lipoproteins in Primary Human Macrophages

B. Staels, M. Colin, J. Fruchart, 2008, Arteriosclerosis, thrombosis, and vascular biology.

Fatty acid composition of brain capillary endothelial cells: effect of the coculture with astrocytes.

M. Lagarde, M. Dehouck, R. Cecchelli, 1995, Journal of lipid research.

Fish-eye disease: structural and in vivo metabolic abnormalities of high-density lipoproteins.

G. Luc, N. Duhal, J. Fruchart, 1997, Metabolism: clinical and experimental.

High-density lipoprotein particles in octogenarians.

G. Luc, J. Fruchart, J. Davignon, 1991, Metabolism: clinical and experimental.

The role of PPARs in atherosclerosis.

B. Staels, J. Fruchart, G. Chinetti, 2002, Trends in molecular medicine.

FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity.

B. Staels, F. Kuipers, O. Barbier, 2003, Gastroenterology.

The UDP-glucuronosyltransferase 1A9 Enzyme Is a Peroxisome Proliferator-activated Receptor α and γ Target Gene*

C. Guillemette, C. Fontaine, B. Staels, 2003, The Journal of Biological Chemistry.

The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene.

C. Guillemette, C. Fontaine, B. Staels, 2003, The Journal of biological chemistry.

Chapter 10 Free radicals and atherosclerosis

J. Fruchart, P. Duriez, 1994 .

Complete atherosclerosis regression after human ApoE gene transfer in ApoE-deficient/nude mice.

J. Caillaud, D. Branellec, J. Fruchart, 2000, Arteriosclerosis, thrombosis, and vascular biology.

Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I.

B. Staels, J. Fruchart, H. Duez, 2001, The Journal of clinical investigation.

Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits.

P. Denéfle, L. Houdebine, J. Caillaud, 1996, Circulation.

DNA Binding-Independent Induction of IκBα Gene Transcription by PPARα

W. V. Berghe, G. Haegeman, B. Staels, 2002 .

PON1, a new biomarker of cardiovascular disease, is low in patients with systemic vasculitis.

E. Hachulla, J. Fruchart, X. Kyndt, 2007, Seminars in arthritis and rheumatism.

Evolution Pattern of Auto-Antibodies against Oxidized Low-Density Lipoproteins in Renal Transplant Recipients

F. Glowacki, J. Fruchart, C. Noël, 2001, Nephron.

Increased levels of high-density lipoprotein cholesterol are ineffective in inhibiting the development of immune responses to oxidized low-density lipoprotein and atherosclerosis in transgenic rabbits expressing human apolipoprotein (apo) A-I with severe hypercholesterolaemia.

J. Caillaud, J. Fruchart, A. Tailleux, 2001, Clinical science.

Detection of autoantibodies against oxidized low-density lipoproteins and of IgG-bound low density lipoproteins in patients with coronary artery disease.

J. Fruchart, M. Hamon, P. Duriez, 1995, Clinica chimica acta; international journal of clinical chemistry.

Immunological and functional properties of in vitro oxidized low density lipoprotein.

J. Fruchart, A. Tailleux, C. Fiévet, 1995, Journal of lipid research.

Immunological properties of apoB-containing lipoprotein particles in human atherosclerotic arteries.

G. Torpier, J. Fruchart, A. Tailleux, 1993, Journal of lipid research.

REDD2 Gene Is Upregulated by Modified LDL or Hypoxia and Mediates Human Macrophage Cell Death

M. Jaye, A. Nègre-Salvayre, J. Fruchart, 2004, Arteriosclerosis, thrombosis, and vascular biology.

Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis.

B. Staels, J. Fruchart, P. Duriez, 1999, Current opinion in lipidology.

Peroxisome Proliferator-Activated Receptor &agr; Reduces Cholesterol Esterification in Macrophages

B. Staels, J. Fruchart, G. Chinetti, 2003, Circulation research.

Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment.

L. Pennacchio, J. Drai, B. Vergès, 2005, The Journal of clinical investigation.

Effects of dietary maritime pine (Pinus pinaster)-seed oil on high-density lipoprotein levels and in vitro cholesterol efflux in mice expressing human apolipoprotein A-I.

J. Dallongeville, J. Fruchart, R. Wolff, 2000, The British journal of nutrition.

The Liver X Receptor Ligand T0901317 Down-regulates APOA5 Gene Expression through Activation of SREBP-1c*

L. Pennacchio, D. Hum, J. Fruchart, 2004, Journal of Biological Chemistry.

Liver X receptors: new players in atherogenesis?

B. Staels, J. Fruchart, L. Millatt, 2003, Current opinion in lipidology.

Effect of simvastatin on plasma lipids, apolipoproteins and lipoprotein particles in patients with primary hypercholesterolaemia

G. Luc, J. Fruchart, P. Drouin, 2004, European Journal of Clinical Pharmacology.

Modulation of the expression of human LDL-Apo B-100 epitopes by lipids and apolipoproteins.

J. Fruchart, A. Tailleux, C. Fiévet, 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element.

J. Dallongeville, D. Hum, B. Staels, 2002, The Journal of clinical investigation.

The farnesoid X receptor induces very low density lipoprotein receptor gene expression

D. Hum, B. Staels, J. Fruchart, 2004, FEBS letters.

Glucose regulates the expression of the farnesoid X receptor in liver.

B. Staels, F. Kuipers, O. Barbier, 2004, Diabetes.

The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia.

A. Zwinderman, J. Kastelein, A. Stalenhoef, 2004, Atherosclerosis.

Circadian variation of postprandial lipemia.

J. Dallongeville, J. Edmé, M. Romon, 1997, The American journal of clinical nutrition.

Peroxisome proliferator-activated receptors and inflammation: from basic science to clinical applications

B. Staels, J. Fruchart, G. Chinetti, 2003, International Journal of Obesity.

ROLE OF PPARs IN INFLAMMATION, ATHEROSCLEROSIS, AND THROMBOSIS

B. Staels, J. Fruchart, H. Duez, 2002 .

PPARs in Inflammation, Atherosclerosis and Thrombosis

B. Staels, J. Fruchart, H. Duez, 2001, Journal of cardiovascular risk.

Insulin-Mediated Down-Regulation of Apolipoprotein A5 Gene Expression through the Phosphatidylinositol 3-Kinase Pathway: Role of Upstream Stimulatory Factor

L. Pennacchio, M. Taskinen, E. Rubin, 2005, Molecular and Cellular Biology.

Phosphorylation-dependent down-regulation of apolipoprotein A5 by insulin

L. Pennacchio, M. Taskinen, E. Rubin, 2004 .

Effect of alcohol intake on human apolipoprotein A-I-containing lipoprotein subfractions.

J. Fruchart, P. Fiévet, N. Ghalim, 1990, Archives of internal medicine.

Residual vascular risk in diabetes - Will the SPPARM alpha concept hold the key?

P. Libby, S. Yamashita, R. Santos, 2019, Diabetes & metabolic syndrome.

PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.

B. Staels, J. Fruchart, C. Fiévet, 2006, Current opinion in pharmacology.

Chymase in exocytosed rat mast cell granules effectively proteolyzes apolipoprotein AI-containing lipoproteins, so reducing the cholesterol efflux-inducing ability of serum and aortic intimal fluid.

P. Kovanen, J. Fruchart, G. Castro, 1996, The Journal of clinical investigation.

Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation

B. Staels, O. Barbier, J. Fruchart, 2003, The Journal of Steroid Biochemistry and Molecular Biology.

Distribution of apolipoprotein E between apo B- and non apo B-containing lipoproteins according to apo E phenotype.

D. Arveiler, G. Luc, F. Cambien, 1997, Atherosclerosis.

Recent developments in the treatment of hypertriglyceridemia

J. Fruchart, P. Duriez, 1999, Current atherosclerosis reports.

PCSK9: The functional relevance of fenofibrate–statin combination therapy to reduce residual cardiovascular risk

J. Fruchart, 2015 .

[The REALIST (REsiduAl risk, LIpids and Standard Therapies) study: an analysis of residual risk attributable to lipid profile in acute coronary syndrome].

F. Sacks, V. Carey, J. Fruchart, 2011, Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion.

Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study.

A. Gotto, S. Grundy, P. Barter, 2006, Journal of the American College of Cardiology.

Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid (TTA) via PPARalpha activation.

L. Madsen, J. Dallongeville, E. Raspé, 1999, Journal of lipid research.

Changes in lipoproteins induced by the remnant kidney tissue or binephrectomy in chronic uremic patients treated by hemodialysis.

J. Fruchart, W. Riesen, R. Jeanmonod, 1989, Metabolism: clinical and experimental.

Angiotensin II type‐I receptor and ACE polymorphisms and risk of myocardial infarction in men and women

A. Evans, C. Morrison, V. Nicaud, 2000, European journal of clinical investigation.

n-3 polyunsaturated fatty acids raise low-density lipoproteins, high-density lipoprotein 2, and plasminogen-activator inhibitor in healthy young men.

J. Fruchart, J. Bard, V. Ollivier, 1991, The American journal of clinical nutrition.

[PPAR gamma: a major nuclear receptor in adipogenesis].

J. Fruchart, P. Gervois, 2003, Medecine sciences : M/S.

Intraperitoneal insulin infusion improves the depletion in choline-containing phospholipids of lipoprotein B particles in type I diabetic patients.

J. Fruchart, T. Crea, B. Guerci, 1996, Metabolism: clinical and experimental.

Multiple coronary heart disease risk factors are associated with menopause and influenced by substitutive hormonal therapy in a cohort of French women.

P. Amouyel, J. Dallongeville, J. Fruchart, 1995, Atherosclerosis.

Expression of apolipoprotein B epitopes in low density lipoproteins of hemodialyzed patients.

J. Fruchart, A. Tailleux, C. Fiévet, 1993, Kidney international.

Reduction of Atherosclerosis by the Peroxisome Proliferator-activated Receptor α Agonist Fenofibrate in Mice*

Y. Chao, S. Wright, A. Tedgui, 2002, The Journal of Biological Chemistry.

Metabolism of apolipoproteins AI and AII in subjects carrying similar apoAI mutations, apoAI Milano and apoAI Paris.

G. Luc, G. Franceschini, C. Sirtori, 2000, Atherosclerosis.

Probucol promotes reverse cholesterol transport in heterozygous familial hypercholesterolemia. Effects on apolipoprotein AI-containing lipoprotein particles.

J. Fruchart, A. Adlouni, M. El Messal, 2000, Atherosclerosis.

Apo A-I Containing Particles and Atherosclerosis

J. Fruchart, P. Duriez, G. Castro, 1995 .

Opposite in vitro and in vivo regulation of hepatic apolipoprotein A-I gene expression by retinoic acid. Absence of effects on apolipoprotein A-II gene expression.

P. Denéfle, B. Staels, D. Branellec, 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

HDL particle measurements: impact for diagnosis and therapy.

J. Fruchart, J. Bard, 1993, Clinical biochemistry.

Apolipoprotein A-I-Containing Particles and Reverse Cholesterol Transport in IDDM

P. Duchateau, J. Fruchart, P. Drouin, 1992, Diabetes.

Binding of apolipoproteins A to adipose cells: role of receptor sites in cholesterol efflux and purification of binding protein(s).

J. Fruchart, V. Clavey, R. Barbaras, 1991, Advances in experimental medicine and biology.

Recent progress in the study of ApoA-containing lipoprotein particles.

J. Fruchart, G. Ailhaud, 1991, Progress in lipid research.

Lipoprotein A-I containing particles.

P. Duchateau, J. Fruchart, N. Théret, 1991, Advances in experimental medicine and biology.

HDL receptor and reverse cholesterol transport in adipose cells.

P. Grimaldi, J. Fruchart, A. Barkia, 1988, Advances in experimental medicine and biology.

Apolipoprotein A-I containing lipoproteins in coronary artery disease.

J. Fruchart, P. Fiévet, M. Bertrand, 1987, Atherosclerosis.

Evaluation of a method for quantitative serum lipoprotein analysis

G. Vanhoutte, J. Fruchart, H. Parra, 1982, La Ricerca in clinica e in laboratorio.

Effects of gender and menopausal status on plasma lipoprotein subspecies and particle sizes.

P. Wilson, G. Luc, J. Ordovás, 1996, Journal of lipid research.

Lipid lowering actions of 7-(2-methylene butyryl)-(2H)-1,4-benzoxazin-3-(4H)-one derivatives in mice, rats and Syrian hamsters.

D. Lesieur, J. Fruchart, J. Sauzieres, 1989, Clinica chimica acta; international journal of clinical chemistry.

Lack of association between genetic variations of apo A-I-C-III-A-IV gene cluster and myocardial infarction in a sample of European male: ECTIM study.

D. Arveiler, F. Cambien, P. Amouyel, 1999, Atherosclerosis.

The role of a triplet repeat sequence of the very low density lipoprotein receptor gene in plasma lipid and lipoprotein level variability in humans.

D. Arveiler, J. Ruidavets, F. Cambien, 1997, Arteriosclerosis, thrombosis, and vascular biology.

Ppar-Alpha in Lipid and Lipoprotein Metabolism, Vascular Inflammation and Atherosclerosis

B. Staels, J. Fruchart, P. Duriez, 2003 .

High-density lipoprotein subclasses and apolipoprotein A-I.

J. Fruchart, P. Duriez, J. Fruchart, 1999, Clinica chimica acta; international journal of clinical chemistry.

Indications and Clinical Use of Fibrates in Specific Lipoprotein Disorders Primary Hypertriglyceridemia

J. Auwerx, J. Dallongeville, K. Schoonjans, 1998 .

HDL heterogeneity and atherosclerosis.

J. Fruchart, A. Tailleux, 1996, Critical reviews in clinical laboratory sciences.

Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR.

J. Auwerx, K. Schoonjans, B. Staels, 1996, Atherosclerosis.

Comparison of the effect of fluvastatin, an hydroxymethyl glutaryl coenzyme A reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by apolipoprotein composition.

J. Dallongeville, J. Fruchart, P. Duriez, 1995, Metabolism: clinical and experimental.

Interaction of LpB, LpB:E, LpB:C-III, and LpB:C-III:E lipoproteins with the low density lipoprotein receptor of HeLa cells.

J. Fruchart, V. Clavey, J. Bard, 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

Quantification of two different types of apolipoprotein A-I containing lipoprotein particles in plasma by enzyme-linked differential-antibody immunosorbent assay.

J. Fruchart, P. Alaupovic, E. Koren, 1987, Clinical chemistry.

Cholesterol efflux from cultured adipose cells is mediated by LpAI particles but not by LpAI:AII particles.

J. Fruchart, R. Barbaras, G. Ailhaud, 1987, Biochemical and biophysical research communications.

Differential electroimmunoassay of human LpA-I lipoprotein particles on ready-to-use plates.

J. Fruchart, J. Bard, H. Mezdour, 1990, Clinical chemistry.

Lipoproteins, apolipoproteins and coronary artery disease assessed by coronary arteriography

J. Fruchart, V. Clavey, M. Bertrand, 1982 .

Plasma apolipoprotein concentrations in young adults with a parental history of premature coronary heart disease and in control subjects. The EARS Study. European Atherosclerosis Research Study.

F. Cambien, G. De Backer, V. Nicaud, 1994, Circulation.

Lipoprotein particles in homozygous familial hypercholesterolemic patients treated with portacaval shunt and LDL apheresis.

P. Amouyel, J. Fruchart, P. Duriez, 1990, Clinica chimica acta; international journal of clinical chemistry.

Comparison of expression and regulation of the high-density lipoprotein receptor SR-BI and the low-density lipoprotein receptor in human adrenocortical carcinoma NCI-H295 cells.

D. Hum, B. Staels, J. Fruchart, 1999, European journal of biochemistry.

Apolipoprotein A-II, HDL metabolism and atherosclerosis.

J. Fruchart, A. Tailleux, V. Clavey, 2002, Atherosclerosis.

Decreased Susceptibility to Diet-Induced Atherosclerosis in Human Apolipoprotein A-II Transgenic Mice

G. Luc, J. Caillaud, J. Fruchart, 2000, Arteriosclerosis, thrombosis, and vascular biology.

High density lipoprotein subfractions, apolipoprotein A‐I containing lipoproteins, lipoprotein (a), and cholesteryl ester transfer protein activity in alcoholic women before and after ethanol withdrawal

M. Taskinen, M. Jauhiainen, C. Ehnholm, 1993, European journal of clinical investigation.

Peroxisome Proliferator–activated Receptor Activators Inhibit Oxidized Low-density Lipoprotein–induced Endothelin-1 Secretion in Endothelial Cells

B. Staels, J. Fruchart, P. Delerive, 2002, Journal of cardiovascular pharmacology.

Characterization of a monoclonal antibody that binds to apolipoprotein E and to lipoprotein of human plasma containing apo E. Applications to ELISA quantification of plasma apo E.

J. Fruchart, V. Clavey, N. Vu-dac, 1988, Journal of immunoassay.

Relationship between low‐density lipoprotein size and apolipoprotein A‐I‐containing particles: the ECTIM study

D. Arveiler, G. Luc, F. Cambien, 1997, European journal of clinical investigation.

Interstitial fluid apolipoprotein A-II: an association with the occurrence of myocardial infarction.

G. Luc, J. Fruchart, Z. Majd, 1996, Atherosclerosis.

Effects of dietary maritime pine seed oil on lipoprotein metabolism and atherosclerosis development in mice expressing human apolipoprotein B

J. Dallongeville, J. Fruchart, R. Wolff, 2001, European journal of nutrition.

Pinus pinaster oil affects lipoprotein metabolism in apolipoprotein E-deficient mice.

J. Dallongeville, J. Fruchart, R. Wolff, 1999, The Journal of nutrition.

Cholesterol efflux, lecithin-cholesterol acyltransferase activity, and pre-beta particle formation by serum from human apolipoprotein A-I and apolipoprotein A-I/apolipoprotein A-II transgenic mice consistent with the latter being less effective for reverse cholesterol transport.

E. Rubin, P. Denéfle, J. Fruchart, 1997, Biochemistry.

Postprandial Dyslipidemia: A Risk Factor for Coronary Heart Disease

J. Dallongeville, J. Fruchart, Jean Dallongeville, 1998, Annals of Nutrition and Metabolism.

Postprandial lipaemia is associated with increased levels of apolipoprotein A-IV in the triacylglycerol-rich fraction and decreased levels in the denser plasma fractions

G. Luc, J. Dallongeville, J. Fruchart, 1997, British Journal of Nutrition.

HDLs and alimentary lipemia. Studies in men with previous myocardial infarction at a young age.

A. Hamsten, F. Karpe, J. Fruchart, 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

Effects of Pinus pinaster and Pinus koraiensis seed oil supplementation on lipoprotein metabolism in the rat

Robert L. Wolff, J. Dallongeville, B. Staels, 1999, Lipids.

Comparison of maritime pine oil and fish oil effects on plasma lipoproteins in apolipoprotein E-deficient mice.

J. Dallongeville, J. Fruchart, R. Wolff, 2000, Prostaglandins, leukotrienes, and essential fatty acids.

Biochemical and Molecular Action of Nutrients Pinus pinaster Oil Affects Lipoprotein Metabolism in Apolipoprotein E-Deficient Mice 1

J. Dallongeville, J. Fruchart, R. Wolff, 1999 .

Lipoprotein particle measurement: an alternative approach to classification of lipid disorders

J. Fruchart, J. Bard, 1991 .

Increased triglyceride levels in shift workers.

M. Romon, J. Fruchart, C. Fiévet, 1992, The American journal of medicine.

Effects of alcohol on lipids and lipoprotein metabolism.

F. Cambien, A. Klatsky, J. Fruchart, 2000 .

The effect of moderate alcohol intake on serum apolipoprotein A-I-containing lipoproteins and lipoprotein (a).

M. Taskinen, M. Jauhiainen, C. Ehnholm, 1991, Metabolism: clinical and experimental.

Serum Lp AI lipoprotein particles and other antiatherogenic lipid parameters in normolipidaemic obese subjects.

J. Fruchart, J. Bard, J. Lecerf, 1996, Diabetes & metabolism.

Effect of smoking cessation on lipoprotein A-I and lipoprotein A-I:A-II levels.

P. Amouyel, J. Dallongeville, M. Fantino, 1997, Metabolism: clinical and experimental.

Apolipoprotein A-I-containing lipoproteins and atherosclerosis

J. Dallongeville, J. Fruchart, A. Leroy, 1995, Current opinion in lipidology.

Plasma concentrations of apolipoprotein A‐I containing particles in normolipidaemic young men

G. Luc, J. Fruchart, H. Parra, 1991, European journal of clinical investigation.

Quantitation of human serum apolipoprotein B by enzyme immunoassay in excess antigen.

J. Fruchart, C. Fiévet, A. Dedieu, 1986, Clinica chimica acta; international journal of clinical chemistry.

Is apolipoprotein A5 a novel regulator of triglyceride‐rich lipoproteins?

J. Fruchart, Heidelinde Jakel, J. Fruchart-Najib, 2006, Annals of medicine.

Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?

T. Kodama, J. Fruchart, M. Hermans, 2021, Current Atherosclerosis Reports.

Apolipoprotein A-I-containing particles and reverse cholesterol transport: evidence for connection between cholesterol efflux and atherosclerosis risk.

J. Fruchart, B. Delfly, G. Castro, 1994, Atherosclerosis.

HDL heterogeneity and coronary heart disease.

J. Fruchart, C. Fiévet, 1991, Diabetes/metabolism reviews.

Lipoprotein heterogeneity and its effect on apolipoprotein assays.

J. Fruchart, 1990, Scandinavian journal of clinical and laboratory investigation. Supplementum.

Quantitative determination of human plasma apolipoprotein A-II by a non competitive enzyme-linked immunosorbent assay.

J. Fruchart, P. Duriez, W. Mcconathy, 1986, Journal of Immunoassay.

Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells.

C. Datz, J. Auwerx, B. Paulweber, 1999, The Journal of endocrinology.

A selective bi-site immunoenzymatic procedure for human Lp[a] lipoprotein quantification using monoclonal antibodies against apo[a] and apoB.

G. Luc, J. Fruchart, H. Mezdour, 1989, Journal of lipid research.

Farnesoid X receptor represses hepatic lipase gene expression Published, JLR Papers in Press, September 1, 2004. DOI 10.1194/jlr.M400221-JLR200

D. Hum, B. Staels, J. Fruchart, 2004, Journal of Lipid Research.

Effects of hypolipidemic drugs on the expression of genes involved in high density lipoprotein metabolism in the rat.

J. Auwerx, B. Staels, J. Fruchart, 1996, Israel journal of medical sciences.

Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition.

J. Fruchart, J. Bard, H. Parra, 1990, Metabolism: clinical and experimental.

Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element.

J. Auwerx, K. Schoonjans, B. Staels, 1994, The Journal of biological chemistry.

Transcriptional regulation of macrophage cholesterol trafficking by PPARα and LXR

B. Staels, J. Fruchart, G. Chinetti, 2006 .

Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy.

B. Staels, J. Fruchart, G. Chinetti-Gbaguidi, 2005, Current opinion in pharmacology.

VascularSMCproliferationisacrucialeventinocclusivecardiovasculardiseases.PPARαisanuclearrecep- torcontrollinglipidmetabolismandinflammation,butitsroleintheregulationofSMCgrowthremains tobeestablished.Here,weshowthatPPARα controlsSMCcell-cycleprogressionattheG 1 /Stransitionby

B. Staels, G. Torpier, O. Barbier, 2005 .

Peroxisome proliferator activated receptors and energy metabolism

B. Staels, J. Fruchart, P. Gervois, 2005 .

Therapeutical effects of PPAR agonists assessed by biomarker modulation

B. Staels, J. Fruchart, G. Chinetti-Gbaguidi, 2005, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

Peroxisome proliferator-activated receptor alpha controls cellular cholesterol trafficking in macrophages.

E. Ikonen, B. Staels, J. Fruchart, 2005, Journal of lipid research.

Fenofibrate Increases Homocystinemia Through a PPAR&agr;-Mediated Mechanism

G. Luc, P. Giral, B. Staels, 2004 .

PPARα controlling HDL metabolism and atherosclerosis

B. Staels, J. Fruchart, Daniel Durán-Sandoval, 2004 .

PPARs: Transcription Factors Controlling Lipid and Lipoprotein Metabolism

B. Staels, J. Fruchart, I. Pineda-Torra, 2002, Annals of the New York Academy of Sciences.

Induction of the Phospholipid Transfer Protein Gene Accounts for the High Density Lipoprotein Enlargement in Mice Treated with Fenofibrate*

G. Luc, A. Tall, L. Lagrost, 2001, The Journal of Biological Chemistry.

Peroxisome Proliferator-activated Receptor α Is Not Rate-limiting for the Lipoprotein-lowering Action of Fish Oil*

J. Dallongeville, J. Peters, F. Gonzalez, 2001, The Journal of Biological Chemistry.

Results PPAR Mediates the Acute Antiinflammatory Action of Simvastatin In Vivo

D. Dombrowicz, B. Staels, O. Barbier, 1996 .

Lipoprotein composition changes induced by fenofibrate in dysbetalipoproteinemia type III.

J. Fruchart, J. Davignon, J. Bard, 1989, Atherosclerosis.

Enzyme immunoassay for human apolipoprotein B, the major protein moiety in low-density- and very-low-density lipoproteins.

A. Capron, J. Fruchart, D. Bout, 1978, Clinical chemistry.

Heterozygosity for ABCA1 gene mutations: effects on enzymes, apolipoproteins and lipoprotein particle size.

A. Zwinderman, M. Hayden, M. Jauhiainen, 2003, Atherosclerosis.

Modulation of Cholesterol Efflux from Fu5AH Hepatoma Cells by the Apolipoprotein Content of High Density Lipoprotein Particles.

P. Gambert, L. Lagrost, J. Fruchart, 1995, The Journal of Biological Chemistry.

Atheroprotective Effect of Human Apolipoprotein A5 in a Mouse Model of Mixed Dyslipidemia

B. Staels, J. Fruchart, C. Fiévet, 2008, Circulation research.

Inflammation, dyslipidaemia, diabetes and PPARs: pharmacological interest of dual PPARα and PPARγ agonists

B. Staels, J. Fruchart, P. Gervois, 2004 .

Plasma level of lipoprotein Lp(a) is high in predialysis or hemodialysis, but not in CAPD.

J. Fruchart, A. Kandoussi, D. Pagniez, 1992, Kidney international.

HDL and triglyceride as therapeutic targets

J. Fruchart, P. Duriez, 2002, Current opinion in lipidology.

Post-statin approaches to hyperlipidaemia.

J. Fruchart, P. Duriez, 1998, Expert opinion on investigational drugs.

Is cholesterol the major lipoprotein C. J. Packard? risk factor in coronary heart disease? - a Franco-Scottish overview

J. Fruchart, 1997 .

Effect of Pravastatin on Angiographic Restenosis After Coronary Balloon Angioplasty fn1fn1This study was supported by a grant from Bristol Myers Squibb Laboratories, Paris.

A. Castaigne, J. Cassagnes, E. Belle, 1997 .

Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes

M. Taskinen, A. Hiukka, J. Fruchart, 2005, Diabetologia.

Selective Peroxisome Proliferator–Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?

J. Fruchart, M. Hermans, J. Fruchart-Najib, 2020, Current Atherosclerosis Reports.

Combination lipid therapy in type 2 diabetes.

F. Sacks, V. Carey, J. Fruchart, 2010, The New England journal of medicine.

The PPARα Activator Fenofibrate Slows Down the Progression of the Left Ventricular Dysfunction in Porcine Tachycardia-Induced Cardiomyopathy

D. Lacroix, B. Staels, G. Torpier, 2007, Journal of cardiovascular pharmacology.

Postprandial Leptin Response to Carbohydrate and Fat Meals in Obese Women

J. Dallongeville, M. Romon, J. Fruchart, 2003, Journal of the American College of Nutrition.

Evidence that reduced lipoprotein lipase activity is not a primary pathogenetic factor for hypertriglyceridemia in renal failure.

J. Dallongeville, P. Nilsson-ehle, H. Thysell, 1995, Kidney international.

SR-BI does not require raft/caveola localisation for cholesteryl ester selective uptake in the human adrenal cell line NCI-H295R.

G. Torpier, J. Fruchart, O. Briand, 2003, Biochimica et biophysica acta.

Potential regulatory role of the farnesoid X receptor in the metabolic syndrome.

B. Staels, J. Fruchart, B. Cariou, 2005, Biochimie.

Variations in Apolipoproteins Serum Amyloid A, A-I, A-II, and C-III in Severely Head-Injured Patients

S. Visvikis, J. Fruchart, P. Métais, 1990, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.

Measurement of arterial wall thickness as a surrogate marker for atherosclerosis.

A. Smit, J. Kastelein, J. Fruchart, 2004, Circulation.

Regulation of the scavenger receptor BI and the LDL receptor by activators of aldosterone production, angiotensin II and PMA, in the human NCI-H295R adrenocortical cell line.

B. Staels, J. Fruchart, V. Clavey, 2003, Biochimica et biophysica acta.

Lack of toxic effects of F 12511, a novel potent inhibitor of acyl-coenzyme A: cholesterol O-acyltransferase, on human adrenocortical cells in culture.

F. Colpaert, B. Staels, G. Torpier, 2001, Biochemical pharmacology.

Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists.

B. Staels, J. Fruchart, Takaaki Araki, 2007, Bioorganic & Medicinal Chemistry Letters.

Apolipoprotein A5, a Crucial Determinant of Plasma Triglyceride Levels, Is Highly Responsive to Peroxisome Proliferator-activated Receptor α Activators*

L. Pennacchio, E. Rubin, B. Staels, 2003, The Journal of Biological Chemistry.

Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists.

B. Staels, J. Fruchart, Keisuke Inoue, 2007, Bioorganic & medicinal chemistry letters.

Connection between cholesterol efflux and atherosclerosis

J. Fruchart, G. Castro, C. D. Geteire, 1995 .

Lipoproteins containing apolipoprotein A-IV: composition and relation to cholesterol esterification.

J. Fruchart, N. Théret, G. Castro, 1994, Biochimica et biophysica acta.

Biochemical characterization of the three major subclasses of lipoprotein A-I preparatively isolated from human plasma.

P. Duchateau, D. Rader, H. Brewer, 1993, Biochemistry.

Tangier disease: isolation and characterization of LpA-I, LpA-II, LpA-I: A-II and LpA-IV particles from plasma.

P. Duchateau, D. Rader, H. Brewer, 1993, Biochimica et biophysica acta.

Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR.

B. Staels, J. Fruchart, G. Chinetti, 2004, Biochemical and biophysical research communications.

Leptin response to carbohydrate or fat meal and association with subsequent satiety and energy intake.

J. Dallongeville, M. Romon, J. Fruchart, 1999, The American journal of physiology.

Short term response of circulating leptin to feeding and fasting in man: influence of circadian cycle

J. Auwerx, C. L. Fur, J. Dallongeville, 1998, International Journal of Obesity.

Black-white differences in serum Lp(a) lipoprotein levels.

J. Fruchart, H. Parra, C. Demarquilly, 1987, Clinica chimica acta; international journal of clinical chemistry.

The increased plasma Lp(a): B lipoprotein particle concentration in angina pectoris is not associated with hypofibrinolysis.

M. Alessi, J. Fruchart, P. Joly, 1990, Clinica chimica acta; international journal of clinical chemistry.

Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR.

B. Staels, J. Fruchart, G. Chinetti, 2004, Biochemical and biophysical research communications.

The Protein Kinase C Signaling Pathway Regulates a Molecular Switch between Transactivation and Transrepression Activity of the Peroxisome Proliferator-Activated Receptor α

B. Staels, J. Fruchart, C. Blanquart, 2004 .

The role of the orphan nuclear receptor Rev-Erbα in adipocyte differentiation and function

C. Fontaine, B. Staels, S. Laitinen, 2005 .

Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.

J. Fruchart, P. Duriez, 2006, Drugs of today.

Glucose regulates LXRα subcellular localization and function in rat pancreatic β-cells

C. Sergheraert, F. Pattou, J. Fruchart, 2006, Cell Research.

The plasma and lipoprotein triglyceride postprandial response to a carbohydrate tolerance test differs in lean and massively obese normolipidemic women.

J. Dallongeville, D. Lairon, M. Romon, 2002, The Journal of nutrition.

Human Nutrition and Metabolism The Plasma and Lipoprotein Triglyceride Postprandial Response to a Carbohydrate Tolerance Test Differs in Lean and Massively Obese Normolipidemic Women 1

J. Dallongeville, D. Lairon, M. Romon, 2002 .

Confusion of apolipoprotein E phenotyping by serum amyloid A.

J. Fruchart, R. Saïle, H. Parra, 1989, Clinical Chemistry.

High-density-lipoprotein subfraction 3 interaction with glycosylphosphatidylinositol-anchored proteins.

G. Torpier, J. Fruchart, O. Briand, 1997, The Biochemical journal.

Purification of an apolipoprotein A binding protein from mouse adipose cells.

J. Fruchart, R. Barbaras, A. Pradines-Figuères, 1990, The Biochemical journal.

PPARs: a new target for neuroprotection

R. Bordet, J. Fruchart, P. Gele, 2005, Journal of Neurology, Neurosurgery & Psychiatry.

Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators.

B. Staels, J. Fruchart, P. Delerive, 2000, The Journal of biological chemistry.

Characterization and functional studies of lipoproteins, lipid transfer proteins, and lecithin:cholesterol acyltransferase in CSF of normal individuals and patients with Alzheimer's disease.

J. Vandekerckhove, P. Santens, M. Rosseneu, 2000, Journal of lipid research.

Peroxisome Proliferator–Activated Receptor &agr; Induces NADPH Oxidase Activity in Macrophages, Leading to the Generation of LDL with PPAR-&agr; Activation Properties

A. Shah, R. Brandes, A. Nohara, 2004 .

Peroxisome Proliferator–Activated Receptor (cid:1) Induces NADPH Oxidase Activity in Macrophages, Leading to the Generation of LDL with PPAR- (cid:1) Activation Properties

R. Brandes, A. Nohara, B. Staels, 2004 .

Peroxisome Proliferator-Activated Receptor-α Activation as a Mechanism of Preventive Neuroprotection Induced by Chronic Fenofibrate Treatment

D. Leys, R. Bordet, R. Cecchelli, 2003, The Journal of Neuroscience.

Potential gene therapy for lecithin-cholesterol acyltransferase (LCAT)-deficient and hypoalphalipoproteinemic patients with adenovirus-mediated transfer of human LCAT gene.

G. Luc, E. Rubin, P. Denéfle, 1996, Circulation.

Development of a radial immunodiffusion technique employing monoclonal antibodies for apolipoprotein B determination in human plasma.

J. Fruchart, S. Marcovina, C. Fiévet, 1985, Clinica chimica acta; international journal of clinical chemistry.

Apolipoprotein B measurement in blood spotted on paper

J. Fruchart, Y. Moschetto, J. Farriaux, 1982, La Ricerca in clinica e in laboratorio.

Genetically-engineered animals as research models for atherosclerosis: their use for the characterization of PPAR agonists in the treatment of cardiometabolic disorders.

B. Staels, J. Fruchart, C. Fiévet, 2007, Frontiers in bioscience : a journal and virtual library.

P eroxisome Proliferator-Activated Receptors at the rossroads of Obesity , Diabetes , and Cardiovascular Disease

B. Staels, J. Fruchart, ndries J. Gilde, 2006 .

The RXR Agonist Bexarotene Improves Cholesterol Homeostasis and Inhibits Atherosclerosis Progression in a Mouse Model of Mixed Dyslipidemia

B. Staels, F. Kuipers, G. Torpier, 2006, Arteriosclerosis, thrombosis, and vascular biology.

Nondiabetic Mouse Model of Mixed Dyslipidemia , Activators Decrease Macrophage-Laden Atherosclerotic Lesions

G. Torpier, J. Fruchart, A. Tailleux, 2005 .

PPAR&agr;, but not PPAR&ggr;, Activators Decrease Macrophage-Laden Atherosclerotic Lesions in a Nondiabetic Mouse Model of Mixed Dyslipidemia

B. Staels, G. Torpier, J. Fruchart, 2005 .

Murine models to investigate pharmacological compounds acting as ligands of PPARs in dyslipidemia and atherosclerosis.

B. Staels, G. Torpier, J. Fruchart, 2003, Trends in pharmacological sciences.

Protection Against Atherogenesis in Mice Mediated by Human Apolipoprotein A-IV

P. Denéfle, J. Caillaud, J. Fruchart, 1996, Science.

Characterization of apoA-IV-containing lipoprotein particles isolated from human plasma and interstitial fluid.

J. Fruchart, G. Castro, G. Ailhaud, 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

HDL metabolic activities in a boy with lipoprotein lipase deficiency and his family

F. Henriksen, J. Fruchart, F. Brites, 2004, European journal of clinical investigation.

Lipoprotein lipase gene polymorphisms: associations with myocardial infarction and lipoprotein levels, the ECTIM study. Etude Cas Témoin sur l'Infarctus du Myocarde.

D. Arveiler, G. Luc, L. Tiret, 1995, Journal of lipid research.

New Risk Factors for Atherosclerosis and Patient Risk Assessment

J. Kastelein, E. Stroes, J. Fruchart, 2004, Circulation.

The role of the orphan nuclear receptor Rev-Erb alpha in adipocyte differentiation and function.

C. Fontaine, B. Staels, S. Laitinen, 2005, Biochimie.

Serum apolipoprotein A-II, a biochemical indicator of alcohol abuse.

J. Fruchart, M. Fontan, P. Puchois, 1984, Clinica chimica acta; international journal of clinical chemistry.

Heterogeneity of High Density Lipoprotein Particles

J. Fruchart, J. Bard, G. Ailhaud, 1993, Circulation.

Adipophilin increases triglyceride storage in human macrophages by stimulation of biosynthesis and inhibition of β‐oxidation

M. Jaye, J. Fruchart, M. Rouis, 2006, The FEBS journal.

Paraoxonase activity is reduced by a pro-atherosclerotic diet in rabbits.

J. Caillaud, J. Fruchart, A. Tailleux, 2000, Biochemical and biophysical research communications.

Oxidized low density lipoproteins exert arrhythmogenic effects in rabbit Purkinje fibers.

J. Fruchart, B. Dupuis, P. Duriez, 1992, Biochemical and biophysical research communications.

Modified low density lipoproteins activate human macrophages to secrete immunoreactive endothelin

J. Fruchart, P. Duriez, F. Martin-Nizard, 1991, FEBS letters.

Effects of fenofibrate, gemfibrozil and nicotinic acid on plasma lipoprotein levels in normal and hyperlipidemic mice. A proposed model for drug screening.

J. Fruchart, V. Clavey, D. Marzin, 1988, Atherosclerosis.

Functional characterization of human recombinant apolipoprotein AIV produced in Escherichia coli.

J. Taylor, P. Denéfle, J. Mayaux, 1991, European journal of biochemistry.

Characterization of angiogenin receptors on bovine brain capillary endothelial cells.

M. Dehouck, R. Cecchelli, J. Fruchart, 1991, Biochemical and biophysical research communications.

Role of Apolipoprotein a IV in Promotion of Cellular Cholesterol Efflux from Adipose Cells

J. Fruchart, R. Barbaras, G. Ailhaud, 1989 .

Daily melatonin supplementation in mice increases atherosclerosis in proximal aorta.

D. Lesieur, G. Torpier, J. Fruchart, 2002, Biochemical and biophysical research communications.

Fat ingestion is associated with increased levels of apoC‐III‐ and apoE‐B‐containing lipoprotein particles in humans

J. Dallongeville, J. Fruchart, E. Baugé, 1997, European journal of clinical investigation.

The hypolipidemic action of bezafibrate therapy in hypertriglyceridemia is mediated by upregulation of lipoprotein lipase: no effects on VLDL substrate affinity to lipolysis or LDL receptor binding.

F. H. Man, A. Van der Laarse, L. Havekes, 2000, Atherosclerosis.

Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates.

J. Auwerx, B. Staels, J. Fruchart, 1997, Arteriosclerosis, thrombosis, and vascular biology.

Low-Density Lipoprotein for Delivery of an Acrylophenone Antineoplastic Molecule into Malignant Cells 1

D. Lesieur, G. Favre, J. Fruchart, 2006 .

Structure-activity relationships in a series of melatonin analogues with the low-density lipoprotein oxidation model.

D. Lesieur, J. Fruchart, P. Duriez, 1999, Free radical biology & medicine.

Rapid quantification of alpha-tocopherol in plasma and low- and high-density lipoproteins.

G. Luc, J. Fruchart, P. Duriez, 1996, Clinical chemistry.

Systemic tissue inhibitor of metalloproteinase‐1 gene delivery reduces neointimal hyperplasia in balloon‐injured rat carotid artery

K. Walsh, J. Fruchart, M. Rouis, 2002, FEBS letters.

Expression, location and cross-reactivity of two antigenic sites on the amino terminal region of rabbit and human apolipoprotein A-I.

F. Pio, J. Fruchart, N. Théret, 1989, Atherosclerosis.

[Focus on the classification of plasma lipoproteins].

J. Fruchart, P. Alaupovic, P. Puchois, 1985, Annales de biologie clinique.

A high concentration of melatonin inhibits in vitro LDL peroxidation but not oxidized LDL toxicity toward cultured endothelial cells.

D. Lesieur, J. Fruchart, S. Lestavel, 1998, Journal of cardiovascular pharmacology.

Antioxidant Therapy and Uptake of Human Oxidized LDL by Macrophages

J. Fruchart, V. Clavey, J. Sauzieres, 1989 .

Binding characteristics of high density lipoprotein subclasses to porcine liver, adrenal and skeletal muscle plasma membranes.

T. van Gent, J. Fruchart, A. van Tol, 1989, The International journal of biochemistry.

Relationship in adipose cells between the presence of receptor sites for high density lipoproteins and the promotion of reverse cholesterol transport.

P. Grimaldi, J. Fruchart, A. Barkia, 1987, Biochemical and biophysical research communications.

Glucose regulates the expression of the apolipoprotein A5 gene.

L. Pennacchio, J. Fruchart, C. Rommens, 2008, Journal of molecular biology.

Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models.

P. Denéfle, J. Caillaud, D. Branellec, 1999, Circulation.

Oxidized High-Density Lipoproteins Modulate Endothelin Secretion by Adult Bovine Aortic Endothelial Cells

J. Fruchart, P. Duriez, A. Boullier, 1995, Journal of cardiovascular risk.

Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E.

J. Fruchart, V. Clavey, J. Bard, 1995, Arteriosclerosis, thrombosis, and vascular biology.

Peroxisome Proliferator-Activated Receptor Regulation of Human ApoA-I by Gemfibrozil and Fenofibrate Through Selective

J. Peters, F. Gonzalez, B. Lefebvre, 2005 .

Expression and secretion of human apolipoprotein A‐I in the heart

N. Baroukh, L. Fiette, J. Fruchart, 2004, FEBS letters.

Analysis of Apolipoprotein A5, C3, and Plasma Triglyceride Concentrations in Genetically Engineered Mice

L. Pennacchio, N. Baroukh, E. Rubin, 2004, Arteriosclerosis, thrombosis, and vascular biology.

Expression of human apolipoprotein A‐I/C‐III/A‐IV gene cluster in mice reduces atherogenesis in response to a high fat‐high cholesterol diet

N. Baroukh, B. Staels, J. Fruchart, 2001, FEBS letters.

Expression of Human Apolipoprotein A-I/C-III/A-IV Gene Cluster in Mice Induces Hyperlipidemia but Reduces Atherogenesis

N. Baroukh, J. Fruchart, L. Vergnes, 2000, Arteriosclerosis, thrombosis, and vascular biology.

High density lipoproteins and coronary heart disease. Future prospects in gene therapy.

J. Fruchart, P. Duriez, 1998, Biochimie.

Branched synthetic peptide constructs mimic cellular binding and efflux of apolipoprotein AI in reconstituted high density lipoproteins.

M. Rosseneu, B. Vanloo, J. Fruchart, 1998, Atherosclerosis.

Endothelial derived vasorelaxation is impaired in human APO A-I transgenic rabbits.

P. Denéfle, J. Fruchart, G. Lebuffe, 1997, Biochemical and biophysical research communications.

Subclasses of LpA‐I in coronary artery disease: distribution and cholesterol efflux ability

J. Fruchart, C. Fiévet, B. Derudas, 1997, European journal of clinical investigation.

Transgenic rabbits expressing human apolipoprotein A-I in the liver.

P. Denéfle, B. Laine, J. Fruchart, 1996, Arteriosclerosis, thrombosis, and vascular biology.

Structure-Function Relationships of Apolipoprotein A-I Variants

A. Jonas, J. Fruchart, H. Funke, 1993 .

Oxidised LDL Modulates Endothelin Secretion by Adult Bovine Aortic Endothelial Cells

J. Fruchart, P. Duriez, A. Boullier, 1995 .

Differential role of apolipoprotein AI-containing particles in cholesterol efflux from adipose cells.

G. Torpier, J. Fruchart, A. Barkia, 1991, Atherosclerosis.

Apolipoprotein B metabolism in homozygous familial hypercholesterolemia.

J. Fruchart, P. Duriez, R. Clegg, 1989, Journal of lipid research.

Identification of Rev-erbalpha as a physiological repressor of apoC-III gene transcription.

E. Raspé, C. Fontaine, B. Staels, 2002, Journal of lipid research.

Identification of Reverb as a physiological repressor of apoC-III gene transcription 1

E. Raspé, C. Fontaine, B. Staels, 2002 .

The human fatty acid transport protein-1 (SLC27A1; FATP-1) cDNA and gene: organization, chromosomal localization, and expression.

J. Auwerx, S. Deeb, L. Gelman, 2000, Genomics.

In vivo glucosylated LpA-I subfraction. Evidence for structural and functional alterations.

C. Slomianny, J. Fruchart, P. Drouin, 1997, Arteriosclerosis, thrombosis, and vascular biology.

Phenylpropanoids from Ballota nigra L. inhibit in vitro LDL peroxidation

J. Fruchart, F. Tillequin, P. Duriez, 2000, Phytotherapy research : PTR.

Enhanced cholesterol efflux promotion in well-trained soccer players.

J. Fruchart, F. Brites, C. de Geitère, 2004, Metabolism: clinical and experimental.

Scavenger receptor BI (SR-BI) mediates a higher selective cholesteryl ester uptake from LpA-I compared with LpA-I:A-II lipoprotein particles.

J. Fruchart, H. Greten, F. Rinninger, 2003, Atherosclerosis.

Selective uptake of cholesteryl esters from high-density lipoprotein-derived LpA-I and LpA-I:A-II particles by hepatic cells in culture.

J. Fruchart, H. Greten, E. Windler, 1998, Biochimica et biophysica acta.

HDL3-signalling in HepG2 cells involves glycosyl-phosphatidylinositol-anchored proteins.

J. Fruchart, S. Nion, F. Nazih-Sanderson, 1997, Biochimica et biophysica acta.

Molecular Mechanism of the Blockade of Plasma Cholesteryl Ester Transfer Protein by Its Physiological Inhibitor Apolipoprotein CI*

P. Gambert, L. Lagrost, Laure Dumont, 2005, Journal of Biological Chemistry.

Pleiotropic effects of fibrates

B. Staels, J. Fruchart, G. Chinetti-Gbaguidi, 2005, Current atherosclerosis reports.

Peroxisome Proliferator-activated Receptor α (PPARα) Turnover by the Ubiquitin-Proteasome System Controls the Ligand-induced Expression Level of Its Target Genes*

B. Staels, O. Barbier, J. Fruchart, 2002, The Journal of Biological Chemistry.

Sequential ultracentrifugation micromethod for separation of serum lipoproteins and assays of lipids, apolipoproteins, and lipoprotein particles.

J. Fruchart, V. Clavey, J. Bard, 1993, Clinical chemistry.

Human Plasma Lipoproteins

J. Shepherd, J. Fruchart, 1989 .

The effect of growth hormone on low-density lipoprotein cholesterol and lipoprotein (a) levels in familial hypercholesterolemia.

S. Tonstad, T. Hagve, J. Fruchart, 1996, Metabolism: clinical and experimental.

Fatty acid saturation of the diet and plasma lipid concentrations, lipoprotein particle concentrations, and cholesterol efflux capacity.

J. Fruchart, G. Castro, P. Mata, 2002, The American journal of clinical nutrition.

Liver X Receptor Activation Controls Intracellular Cholesterol Trafficking and Esterification in Human Macrophages

E. Ikonen, M. Bouhlel, C. Fontaine, 2005, Circulation research.

Fibrates increase human REV-ERBalpha expression in liver via a novel peroxisome proliferator-activated receptor response element.

V. Laudet, B. Staels, J. Fruchart, 1999, Molecular endocrinology.

Natural phenylpropanoids inhibit lipoprotein‐induced endothelin‐1 secretion by endothelial cells

S. Şahpaz, J. Fruchart, P. Duriez, 2004, The Journal of pharmacy and pharmacology.

Transcriptional Regulation of Apolipoprotein C-III Gene Expression by the Orphan Nuclear Receptor RORα*

J. Mariani, E. Raspé, B. Staels, 2001, The Journal of Biological Chemistry.

Cholesterol efflux from adipose cells is coupled to diacylglycerol production and protein kinase C activation.

G. Vassaux, J. Fruchart, N. Théret, 1990, Biochemical and biophysical research communications.

Perilipin, a potential substitute for adipophilin in triglyceride storage in human macrophages.

M. Jaye, M. Bouhlel, J. Fruchart, 2006, Atherosclerosis.

Effect of Fenofibrate on Lipoprotein Particles Predictive of Coronary Atherosclerosis

J. Fruchart, P. Drouin, S. Marcovina, 1987 .

PPARγ3 mRNA: a distinct PPARγ mRNA subtype transcribed from an independent promoter

J. Auwerx, L. Fajas, J. Fruchart, 1998 .

The orphan nuclear receptor ROR alpha is a negative regulator of the inflammatory response.

J. Mariani, D. Monté, B. Staels, 2001, EMBO reports.

Evidence of non-deficient low-density lipoprotein receptor patients in a pool of subjects with clinical familial hypercholesterolemia profile.

G. Luc, J. Fruchart, S. Benhamamouch, 1994, Metabolism: clinical and experimental.

CYS127S (FH-Kairouan) and D245N (FH-Tozeur) mutations in the LDL receptor gene in Tunisian families with familial hypercholesterolaemia

J. Fruchart, V. Clavey, S. Lestavel, 2002, Journal of medical genetics.

Diverse effect of ethnicity on plasma lipoprotein[a] levels in heterozygote patients with familial hypercholesterolemia.

Y. Friedlander, S. Eisenberg, J. Fruchart, 1991, Journal of lipid research.

A phenocopy of type III dysbetalipoproteinemia occurring in a candidate family for a putative apo E receptor defect.

A. Kessling, J. Dallongeville, J. Fruchart, 1991, Annals of medicine.

Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability.

J. Fruchart, M. Rouis, M. Chapman, 2004, Atherosclerosis.

Lack of Triglyceride-Lowering Properties of Fish Oil in Apolipoprotein E–Deficient Mice

J. Dallongeville, J. Fruchart, J. Fruchart, 2001, Arteriosclerosis, thrombosis, and vascular biology.

Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis.

J. Fruchart, H. Mezdour, H. Parra, 1987, Clinical chemistry.

Association of synthetic peptide fragments of human apolipoprotein A-I with phospholipids.

R. Brasseur, L. Lins, M. Rosseneu, 1995, Journal of lipid research.

Increased Susceptibility of Low-Density Lipoprotein to Ex Vivo Oxidation in Mice Transgenic for Human Apolipoprotein B Treated with 1 Melatonin-Related Compound Is Not Associated with Atherosclerosis Progression

R. Bordet, D. Lesieur, G. Torpier, 2005, Journal of cardiovascular pharmacology.

Measurement of apolipoprotein B concentration in plasma lipoproteins by combining selective precipitation and mass spectrometry.

G. Luc, N. Duhal, L. Béghin, 2000, Journal of lipid research.

Human very low density lipoprotein structure: interaction of the C apolipoproteins with apolipoprotein B-100.

Y. Xie, H. Pownall, J. Fruchart, 1993, Journal of lipid research.

Interaction of LDL, Lp[a], and reduced Lp[a] with monoclonal antibodies against apoB.

J. Fruchart, S. Marcovina, C. Fiévet, 1988, Journal of lipid research.

Human apolipoprotein B. Evidence for its immunochemical heterogeneity using monoclonal antibodies and an immunoenzymometric assay.

J. Fruchart, C. Fiévet, J. Lecocq, 1988, Clinical biochemistry.

Efficacy and safety of high dose fluvastatin in patients with familial hypercholesterolaemia

S. Eisenberg, J. Fruchart, E. Leitersdorf, 2004, European Journal of Clinical Pharmacology.

A screening method for abnormally high lipoprotein(a) concentrations by agarose lipoprotein electrophoresis.

J. Fruchart, P. Fiévet, C. Fiévet, 1994, Clinica chimica acta; international journal of clinical chemistry.

Distribution of lipid variables in subjects in Belfast, Northern Ireland and Taiyuan, P R China.

F. Cambien, J. Fruchart, J. Bard, 1993, Atherosclerosis.

Transcriptional Regulation of Apolipoprotein A5 Gene Expression by the Nuclear Receptor RORα

L. Pennacchio, D. Hum, B. Staels, 2005, Arteriosclerosis, thrombosis, and vascular biology.

Experimental studies on the regulation of myocardial and adipose tissue lipoprotein lipase activitites in rat.

J. Fruchart, P. Dewailly, J. Jaillard, 1974, Biochemical and biophysical research communications.

Apolipoprotein B signal peptide polymorphism in patients with myocardial infarction and controls

G. Siest, D. Arveiler, F. Cambien, 2004, Human Genetics.

Apolipoprotein B: Immunological Methods for the Detection of Mutants

S. Humphries, A. Dunning, J. Fruchart, 1989 .

A monoclonal antibody (BIP 45) detects Ag(c,g) polymorphism of human apolipoprotein B.

J. Fruchart, P. Duriez, J. Bard, 1987, Journal of immunological methods.

Latex immunoassay of human serum Lp(a+) lipoprotein.

J. Fruchart, P. Duthilleul, N. Vu-dac, 1985, Journal of lipid research.

Variations in lipoproteins during aminoglutethimide therapy

J. Fruchart, N. Ghalim, J. Bonneterre, 1987, Breast Cancer Research and Treatment.

Apolipoprotein B polymorphism and altered apolipoprotein B concentrations in Congolese blacks

J. Fruchart, P. Duriez, F. Monard, 1991, Clinical genetics.

Lipoproteins and Reconstituted Blood-Brain Barrier

M. Dehouck, R. Cecchelli, S. Méresse, 1991 .

Oxidation of lipoproteins and atherosclerosis.

G. Luc, J. Fruchart, 1991, The American journal of clinical nutrition.

Non-enzymatic glycosylation of apolipoprotein A-I and its functional consequences.

J. Fruchart, P. Drouin, C. Fiévet, 1995, Diabete & metabolisme.

Abnormal capacity to induce cholesterol efflux and a new LpA-I pre-beta particle in type 2 diabetic patients.

M. Rosseneu, J. Fruchart, N. Nicolaïew, 1999, Clinica chimica acta; international journal of clinical chemistry.

Association between epitopes detected by monoclonal antibody BIP‐45 and the Xbal polymorphism of Apolipoprotein B

S. Humphries, A. Dunning, J. Fruchart, 1988, Clinical genetics.

Serum amyloid A concentrations in giant-cell arteritis and polymyalgia rheumatica: a useful test in the management of the disease.

E. Hachulla, J. Fruchart, P. Hatron, 1991, Clinical and experimental rheumatology.

Direct characterization, enrichment and sequencing of differential displayed cDNA sequences

J. Fruchart, J. Zeng, Mingfang Liu, 1998 .

Two-site enzyme immunoassay of cholesteryl ester transfer protein with monoclonal and oligoclonal antibodies.

Y. Marcel, J. Fruchart, A. Tartar, 1994, Clinical chemistry.

Effects of fenofibrate on lipoprotein metabolism and fatty acid distribution in Zucker rats.

J. Fruchart, V. Clavey, D. Marzin, 1988, Atherosclerosis.

A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. The Lovastatin Pravastatin Study Group.

P. Toutouzas, E. Stein, J. Fruchart, 1993, The American journal of cardiology.

The polymorphism ApoB/4311 in patients with myocardial infarction and controls: the ECTIM study

D. Arveiler, F. Cambien, P. Ducimetiere, 1992, Human Genetics.

Enhanced VDUP-1 gene expression by PPARgamma agonist induces apoptosis in human macrophage.

K. Brand, L. Billiet, J. Fruchart, 2008, Journal of cellular physiology.

Familial defective apolipoprotein B-100 and myocardial infarction. The ECTIM study

D. Arveiler, G. Luc, F. Cambien, 1995, Atherosclerosis.

Absence of relationship between plasma Lp(a), Lp-AI, anti-oxidized LDL autoantibodies, LDL immune complexes concentrations and restenosis after percutaneous transluminal coronary angioplasty.

P. Amouyel, J. Fruchart, M. Hamon, 2000, Clinica chimica acta; international journal of clinical chemistry.

Different ways to regulate the PPARalpha stability.

B. Staels, J. Fruchart, C. Blanquart, 2004, Biochemical and biophysical research communications.

Lowering of HDL2-cholesterol and lipoprotein A-I particle levels by increasing the ratio of polyunsaturated to saturated fatty acids.

J. Fruchart, J. Bard, M. Apfelbaum, 1991, The American journal of clinical nutrition.

The Increase of Apolipoprotein A-V During Postprandial Lipemia Parallels the Response of Triglyceride-Rich Lipoproteins in Type 2 Diabetes

M. Taskinen, J. Fruchart, N. Matikainen, 2007, Diabetes Care.

Running title: Postprandial apoA-V in type 2 diabetes

M. Taskinen, J. Fruchart, N. Matikainen, 2007 .

Paraoxonase 1 and platelet-activating factor acetylhydrolase activities in patients with low hdl-cholesterol levels with or without primary hypertriglyceridemia.

J. Fruchart, F. Brites, R. Wikinski, 2004, Archives of medical research.

Pocket guide to prevention of coronary heart disease

J. Fruchart, R. Paoletti, W. Riesen, 2003 .

Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study

S. Grundy, P. Barter, D. Waters, 2006, The Lancet.

Bovine Brain Endothelial Cells Express Tight Junctions and Monoamine Oxidase Activity in Long‐Term Culture

M. Dehouck, R. Cecchelli, S. Méresse, 1989, Journal of neurochemistry.

Peroxisome Proliferator-Activated Receptor β/δ: A novel target for the reduction of atherosclerosis

B. Staels, J. Fruchart, B. Gross, 2005 .

Transient impairment of the adaptive response to fasting in FXR‐deficient mice

A. Grefhorst, F. Gonzalez, T. V. van Dijk, 2005, FEBS letters.

HMG-CoA reductase inhibition and PPAR- alpha activation both inhibit cyclosporin A induced endothelin-1 secretion in cultured endothelial cells.

B. Staels, J. Fruchart, M. Hazzan, 2002, Clinical science.

Genetic Determinants of Responsiveness to the HMG‐CoA Reductase Inhibitor Fluvastatin in Patients With Molecularly Defined Heterozygous Familial Hypercholesterolemia

Y. Friedlander, V. Meiner, S. Eisenberg, 1993, Circulation.

Inflammation, dyslipidaemia, diabetes and PPars: pharmacological interest of dual PPARalpha and PPARgamma agonists.

B. Staels, J. Fruchart, P. Gervois, 2004, International journal of clinical practice. Supplement.

Both Hepatic and Extrahepatic ABCA1 Have Discrete and Essential Functions in the Maintenance of Plasma High-Density Lipoprotein Cholesterol Levels In Vivo

M. Hayden, F. Zimetti, J. Parks, 2006, Circulation.

Influence of mental stress and circadian cycle on postprandial lipemia.

J. Dallongeville, P. Devos, M. Romon, 1999, The American journal of clinical nutrition.

Is There a Role for Paraoxonase in Atherosclerosis and in Antiphospholipid Syndrome

E. Hachulla, J. Fruchart, P. Hatron, 2001 .

Efficacy of sequential hormone replacement therapy in the treatment of hypercholesterolemia among postmenopausal women

S. Tonstad, J. Fruchart, J. Bard, 1995, Journal of internal medicine.

Apolipoprotein C-III, an important player in lipoprotein metabolism

J. Auwerx, G. Luc, J. Dallongeville, 1996 .

[Lipoprotein (a). An additional marker of atherosclerosis].

J. Fruchart, H. Mezdour, H. Parra, 1990, Annales de biologie clinique.

Alpha-Tocopherol But Not Beta-Tocopherol Inhibits Thrombin-Induced PKC Activation and Endothelin Secretion in Endothelial Cells

J. Fruchart, P. Duriez, A. Boullier, 1998, Journal of cardiovascular risk.

Metabolism of lipoproteins in rodent malaria, relationship between lipolysis, steatosis and increased biosynthesis of V.L.D.L.

J. Fruchart, B. Fournet, P. Charet, 1981, Annales de parasitologie humaine et comparee.

Paullinia pinnata Extracts Rich in Polyphenols Promote Vascular Relaxation via Endothelium-dependent Mechanisms

R. Bordet, B. Staels, S. Şahpaz, 2006, Journal of cardiovascular pharmacology.

Differential toxicities of air (mO‐LDL) or copper‐oxidized LDLs (Cu‐LDL) toward endothelial cells

J. Fruchart, P. Duriez, E. Teissier, 1999, Journal of biochemical and molecular toxicology.

Protein kinase C-dependent desensitization of HDL3-activated phospholipase C in human platelets.

J. Goudemand, J. Fruchart, H. Nazih, 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

Pertussis toxin sensitive G-protein coupling of HDL receptor to phospholipase C in human platelets.

J. Fruchart, V. Clavey, H. Nazih, 1992, Thrombosis research.

Paraoxonase activity is dramatically decreased in patients positive for anticardiolipin antibodies

E. Hachulla, J. Fruchart, P. Hatron, 2000, Lupus.

D. Lesieur, J. Fruchart, D. Bonnefont-Rousselot, 2002, Journal of pineal research.

Location of Probucol in Lipoproteins Inferred from Compositional Analysis of Lipoprotein Particles. An In‐vitro Study

S. Urien, J. Tillement, J. Fruchart, 1994, The Journal of pharmacy and pharmacology.

Influence of Oral and Percutaneous Estrogen Therapy on the Lipoprotein Particle Profile of Postmenopausal Women

P. Amouyel, J. Fruchart, J. Bard, 1993 .

Measurement of lipoprotein particles.

J. Fruchart, C. Fiévet, 1998, Methods in molecular biology.

Apolipoprotein E Knockout Mice Over-Expressing Human Tissue Inhibitor of Metalloproteinase 1 Are Protected against Aneurysm Formation but Not against Atherosclerotic Plaque Development

J. Fruchart, M. Slimane, M. Rouis, 2006, Journal of Vascular Research.

Prevention of in vitro low-density lipoprotein oxidation by an albumin-containing Lp A-I subfraction.

J. Fruchart, A. Tailleux, C. Fiévet, 1995, Biochimica et biophysica acta.

On-treatment Levels of HDL-C and the Ratio of LDL-C/HDL-C as Predictors of Cardiovascular Events in the Treating to New Targets (TNT) Study

Bittner, A. Gotto, S. Grundy, 2006 .

Oxidized phospholipids activate PPARalpha in a phospholipase A2-dependent manner.

B. Staels, J. Fruchart, P. Delerive, 2000, FEBS letters.

Influence of serum amyloid A on cholesterol esterification in human plasma.

G. Hocke, J. Fruchart, R. Saïle, 1989, Biochimica et biophysica acta.

The epitopes of apolipoprotein A-I define distinct structural domains including a mobile middle region.

E. Rassart, Y. Marcel, J. Fruchart, 1991, The Journal of biological chemistry.

Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.

Raimund Erbel, Jean-Claude Tardif, Paul Schoenhagen, 2006, JAMA.

Peroxisome proliferator-activated receptor alpha (PPARalpha ) turnover by the ubiquitin-proteasome system controls the ligand-induced expression level of its target genes.

B. Staels, O. Barbier, J. Fruchart, 2002, The Journal of biological chemistry.

Alteration of the lipid and apolipoprotein contents of lipoprotein (a) in haemodialysis patients.

J. Fruchart, H. Parra, A. Tacquet, 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Intramyelinic conversion of cerebrosides into acylgalactosylceramides

J. Fruchart, N. Théret, J. Bourre, 1989, Neurochemical Research.

Changes in fatty acid composition of cardiac mitochondrial phospholipids in rats fed rapeseed oil

J. Fruchart, A. Nouvelot, P. Dewailly, 1978, Lipids.

Changes in rat heart phospholipid composition after rapeseed oil feeding

J. Fruchart, A. Nouvelot, P. Dewailly, 1977, Lipids.

Use of bacterial expression cloning to localize the epitopes for a series of monoclonal antibodies against apolipoprotein B100.

Y. Marcel, J. Scott, R. Pease, 1990, The Journal of biological chemistry.

Apo AIV in plasma and dialysate fluid of CAPD patients: comparison with other apolipoproteins.

J. Fruchart, A. Kandoussi, D. Pagniez, 1992, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Peroxisome proliferator-activated receptor alpha induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR-alpha activation properties.

A. Shah, R. Brandes, A. Nohara, 2004, Circulation research.

[Pharmacology of PPARalpha, PPARgamma and dual PPARalpha/gamma agonists in clinical development].

B. Staels, J. Fruchart, B. Bailleul, 2003, Medecine sciences : M/S.

[PPARs activators and regulation of lipid metabolism, vascular inflammation and atherosclerosis].

B. Staels, J. Fruchart, G. Chinetti, 2001, Journees annuelles de diabetologie de l'Hotel-Dieu.

Effect of fluvastatin on plasma apolipoprotein-B-containing particles, including lipoprotein(a). European Fluvastatin Study Group.

J. Dallongeville, J. Fruchart, J. Bard, 1994, Journal of internal medicine. Supplement.

3P-0816∗ Apolipoprotein A5 is an inflammatory responsive gene down-regulated by tumor necrosis factorα and interleukin-1

L. Pennacchio, E. Rubin, J. Fruchart, 2003 .

The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor alpha.

B. Staels, J. Fruchart, C. Blanquart, 2004, Molecular endocrinology.

Depletion in choline containing phospholipids of LpB particles in adequately controlled type I insulin-dependent diabetes mellitus.

J. Fruchart, P. Drouin, C. Fiévet, 1990, Diabete & metabolisme.

Interactions of high-density lipoprotein 3 with brain capillary endothelial cells.

R. Cecchelli, S. Méresse, J. Fruchart, 1989, Biochimica et biophysica acta.

Identification of specific amphipathic alpha-helical sequence of human apolipoprotein A-IV involved in lecithin:cholesterol acyltransferase activation.

R. Brasseur, S. Cuiné, M. Rosseneu, 1994, The Journal of biological chemistry.

Drug transfer across the blood-brain barrier: comparison of in vitro and in vivo models.

J. Tillement, M. Dehouck, R. Cecchelli, 1993, Advances in experimental medicine and biology.

Interaction of reconstituted high density lipoprotein discs containing human apolipoprotein A-I (ApoA-I) variants with murine adipocytes and macrophages. Evidence for reduced cholesterol efflux promotion by apoA-I(Pro165-->Arg).

P. Duchateau, A. von Eckardstein, G. Assmann, 1993, The Journal of biological chemistry.

Very-low-density lipoprotein of uremic patients is a poor substrate for bovine lipoprotein lipase in vitro.

J. Dallongeville, P. Nilsson-ehle, J. Fruchart, 1996, Metabolism: clinical and experimental.

Cigarette smoking is associated with unhealthy patterns of nutrient intake: a meta-analysis.

P. Amouyel, J. Dallongeville, J. Fruchart, 1998, The Journal of nutrition.

Entry of polyunsaturated fatty acids into the brain: evidence that high-density lipoprotein-induced methylation of phosphatidylethanolamine and phospholipase A2 are involved.

J. Fruchart, J. Bourre, L. Elkhalil, 1996, The Biochemical journal.

Alterations in plasma lipoproteins and apolipoproteins before the age of 40 in heterozygotes for lipoprotein lipase deficiency.

M. Hayden, M. Prins, J. Kastelein, 1996, Journal of lipid research.

Di‐tert‐butylhydroxylated flavonoids protect endothelial cells against oxidized LDL‐induced cytotoxicity

J. Fruchart, P. Duriez, N. Cotelle, 2001, Journal of biochemical and molecular toxicology.

Antioxidant activity of pinoline analogues in the LDL oxidation model

J. Poupaert, D. Lesieur, J. Fruchart, 2002 .

Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity

F. Hu, R. Ross, J. Després, 2020, Nature Reviews Endocrinology.

Lipoprotein abnormalities in chronic haemodialysis patients.

G. Vanhoutte, J. Fruchart, H. Parra, 1988, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids.

T. Kooistra, J. Dallongeville, B. Staels, 1998, The Journal of clinical investigation.

[4‐(2H‐1,2,3‐Benzotriazol‐2‐yl)phenoxy]alkanoic Acids as Agonists of Peroxisome Proliferator‐Activated Receptors (PPARs)

S. Romeo, A. Sparatore, B. Staels, 2006, Chemistry & biodiversity.

Natural phenylpropanoids protect endothelial cells against oxidized LDL-induced cytotoxicity.

J. Fruchart, P. Duriez, F. Bailleul, 2003, Planta medica.

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential

P. Libby, P. Ridker, J. Després, 2019, Cardiovascular Diabetology.

PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway

M. Jaye, H. Brewer, A. Remaley, 2001, Nature Medicine.

Induction of IκBα Expression as a Mechanism Contributing to the Anti-inflammatory Activities of Peroxisome Proliferator-activated Receptor-α Activators*

B. Staels, J. Fruchart, P. Delerive, 2000, The Journal of Biological Chemistry.

Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease.

J. Fruchart, 2009, Atherosclerosis.

PPARα and PPARγ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome

B. Staels, J. Fruchart, C. Fiévet, 2006 .

Sorting out the roles of PPARα in energy metabolism and vascular homeostasis

Philippe Lefebvre, B. Staels, J. Fruchart, 2006 .

Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis.

B. Staels, J. Fruchart, B. Neve, 2000, Biochemical pharmacology.

Comparison between fat intake assessed by a 3-day food record and phospholipid fatty acid composition of red blood cells: results from the Monitoring of Cardiovascular Disease-Lille Study.

J. Lecerf, M. Romon, J. Fruchart, 1995, Metabolism: clinical and experimental.

The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene*

J. Auwerx, J. Flier, D. Auboeuf, 1997, The Journal of Biological Chemistry.

An Easier, Reproducible, and Mass‐Production Method to Study the Blood–Brain Barrier In Vitro

P Delorme, M. Dehouck, R. Cecchelli, 1990, Journal of neurochemistry.

An Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing

Jonathan C. Cohen, D. Cox, R. Krauss, 2001, Science.

Apolipoprotein A-V Modulates Insulin Secretion in Pancreatic β-cells Through its Interaction with Midkine

H. Drobecq, L. Héliot, J. Fruchart, 2009, Cellular Physiology and Biochemistry.

Inhibitory Effects of Specific Apolipoprotein C-III Isoforms on the Binding of Triglyceride-rich Lipoproteins to the Lipolysis-stimulated Receptor*

P. André, V. Lotteau, C. Mann, 1997, The Journal of Biological Chemistry.

Low‐Density Lipoprotein Receptor on Endothelium of Brain Capillaries

R. Cecchelli, S. Méresse, J. Fruchart, 1989, Journal of neurochemistry.

Tissue-Specific Roles of ABCA1 Influence Susceptibility to Atherosclerosis

B. McManus, M. Hayden, J. Parks, 2009, Arteriosclerosis, thrombosis, and vascular biology.

Structure determination of the polymorphism of acylgalactosylceramide in rat brain by gas chromatography/mass spectrometry and proton magnetic resonance.

J. Wieruszeski, J. Fruchart, N. Théret, 1987, Biochimica et biophysica acta.

Plasma Removal of Intravenous Essential Phospholipids in Man

J. Fruchart, P. Dewailly, C. Desreumaux, 1976 .

Residual macrovascular risk in 2013: what have we learned?

A. Gotto, D. Rader, M. Krempf, 2014, Cardiovascular Diabetology.

Regulation of Peroxisome Proliferator-Activated Receptor γ Expression by Adipocyte Differentiation and Determination Factor 1/Sterol Regulatory Element Binding Protein 1: Implications for Adipocyte Differentiation and Metabolism

B. Spiegelman, J. Auwerx, L. Fajas, 1999, Molecular and Cellular Biology.

p300 Interacts with the N- and C-terminal Part of PPARγ2 in a Ligand-independent and -dependent Manner, Respectively*

J. Auwerx, Gaochao Zhou, E. Raspé, 1999, The Journal of Biological Chemistry.

An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer

J. Auwerx, L. Gelman, J. Fruchart, 1999, Cellular and Molecular Life Sciences CMLS.

Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor.

J. Auwerx, J. Dallongeville, K. Schoonjans, 1995, The Journal of clinical investigation.

A truncated human peroxisome proliferator-activated receptor alpha splice variant with dominant negative activity.

B Staels, B. Staels, J. Fruchart, 1999, Molecular endocrinology.

PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a.

B. Staels, G. Torpier, O. Barbier, 2005, The Journal of clinical investigation.

Leptin, a pleiotropic hormone: physiology, pharmacology, and strategies for discovery of leptin modulators.

J. Auwerx, J. Dallongeville, J. Fruchart, 1998, Journal of medicinal chemistry.

p300 interacts with the N- and C-terminal part of PPARgamma2 in a ligand-independent and -dependent manner, respectively.

J. Auwerx, G. Zhou, E. Raspé, 1999, The Journal of biological chemistry.

Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice

J. Auwerx, P. Desreumaux, J. Fruchart, 1998, Nature Medicine.

The Orphan Nuclear Receptor Rev-Erbα Is a Peroxisome Proliferator-activated Receptor (PPAR) γ Target Gene and Promotes PPARγ-induced Adipocyte Differentiation*

S. Mandrup, F. Soncin, C. Fontaine, 2003, Journal of Biological Chemistry.

Activation of Proliferator-activated Receptors α and γ Induces Apoptosis of Human Monocyte-derived Macrophages*

B. Staels, J. Fruchart, G. Chinetti, 1998, The Journal of Biological Chemistry.

Transcriptional control of adipogenesis.

J. Auwerx, L. Fajas, J. Fruchart, 1998, Current opinion in cell biology.

Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates.

J. Auwerx, B. Staels, J. Fruchart, 1997, Arteriosclerosis, thrombosis, and vascular biology.

The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs).

J. Auwerx, K. Schoonjans, B. Staels, 1997, Biochimie.

Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects.

J. Auwerx, K. Schoonjans, B. Staels, 1996, Journal of atherosclerosis and thrombosis.

Peroxisome Proliferator-Activated Receptors at the Crossroads of Obesity, Diabetes, and Cardiovascular Disease

B. Staels, J. Fruchart, A. Gilde, 2006 .

Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice

B. Staels, J. Fruchart, G. Chinetti, 2001, Current opinion in lipidology.

Transcriptional induction of rat liver apolipoprotein A-I gene expression by glucocorticoids requires the glucocorticoid receptor and a labile cell-specific protein.

J. Auwerx, B. Staels, J. Fruchart, 1996, European journal of biochemistry.

Tissue-specific expression of the human gene for lecithin: cholesterol acyltransferase in transgenic mice alters blood lipids, lipoproteins and lipases towards a less atherogenic profile.

G. Luc, B. Staels, G. Olivecrona, 1995, European journal of biochemistry.

Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation

B. Staels, J. Fruchart, G. Chinetti, 2000, Inflammation Research.

Regulation of Lipid and Lipoprotein Metabolism by PPAR Activators

B. Staels, J. Fruchart, I. Torra, 2000, Clinical chemistry and laboratory medicine.

Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study

P. Libby, N. Paynter, P. Ridker, 2018, American heart journal.

Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia

J. Fruchart, 2017, Cardiovascular Diabetology.

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.

Nikolaus Marx, Takashi Kadowaki, Alberto Zambon, 2008, The American journal of cardiology.

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients

F. Sacks, P. Zimmet, C. Wanner, 2008, Diabetes & vascular disease research.

Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

Philip J. Barter, Heiner Greten, A. Gotto, 2005, The New England journal of medicine.

Hawthorn extracts inhibit LDL oxidation.

J. Fruchart, P. Duriez, E. Teissier, 2003, Die Pharmazie.

Modulation of Hepatic Inflammatory Risk Markers of Cardiovascular Diseases by PPAR–&agr; Activators: Clinical and Experimental Evidence

Alberto Zambon, B. Staels, P. Pauletto, 2006, Arteriosclerosis, thrombosis, and vascular biology.

Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-C*

G. Assmann, C. Sirtori, J. Shepherd, 2004, Current medical research and opinion.

The role of fibric acids in atherosclerosis

B. Staels, J. Fruchart, P. Duriez, 2001, Current atherosclerosis reports.

FXR‐deficiency confers increased susceptibility to torpor

Folkert Kuipers, R. Burcelin, B. Staels, 2007, FEBS letters.

Immunoelectron microscopy of low density lipoproteins yields a ribbon and bow model for the conformation of apolipoprotein B on the lipoprotein surface.

V. Schumaker, J. Fruchart, L. Curtiss, 1995, Journal of lipid research.

Transcriptional Regulation of Apolipoprotein A-I Gene Expression by the Nuclear Receptor RORα*

J. Auwerx, J. Mariani, K. Schoonjans, 1997, The Journal of Biological Chemistry.

[Role of the peroxisome proliferator-activated receptors (PPARS) in the regulation of lipids and inflammation control].

B. Staels, J. Fruchart, G. Chinetti, 2002, Journal de la Societe de biologie.

Atherogenic Lipoprotein Particles in Atherosclerosis

J. Fruchart, P. Duriez, R. Carmena, 2004, Circulation.

Apo B-containing lipoprotein particles in poorly controlled insulin-dependent diabetes.

C. Slomianny, J. Fruchart, P. Drouin, 1996, Atherosclerosis.

Electroimmuno- and immunonephelometric assays of apolipoprotein A-I by using a mixture of monoclonal antibodies.

J. Fruchart, C. Fiévet, C. Durieux, 1988, Clinical chemistry.

Antibodies of predetermined specificity to apolipoprotein C-II elicited with a synthetic peptide. Characterization and use for immunoassays.

J. Fruchart, C. Fiévet, A. Tartar, 1988, Journal of immunological methods.

Triglycerides and Risk for Atherosclerotic Disease

G. Luc, J. Fruchart, P. Duriez, 2006 .

Sources of variability of human plasma apolipoprotein A‐IV levels and relationships with lipid metabolism

G. Siest, R. Guéguen, J. Fruchart, 1994, Genetic epidemiology.

Rat monoclonal antibodies to human apolipoprotein B: advantages and applications.

Y. Marcel, H. Bazin, J. Fruchart, 1989, Journal of lipid research.

Chemical approach to synthetic immunogens in clinical chemistry.

J. Fruchart, C. Fiévet, A. Tartar, 1987, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

Regulation of rat liver apolipoprotein A-I, apolipoprotein A-II and acyl-coenzyme A oxidase gene expression by fibrates and dietary fatty acids.

J. Auwerx, P. Calder, P. Denéfle, 1995, European journal of biochemistry.

Safety issues and prospects for future generations of PPAR modulators.

D. Hum, B. Staels, J. Fruchart, 2007, Biochimica et biophysica acta.

Induction of the Fatty Acid Transport Protein 1 and Acyl-CoA Synthase Genes by Dimer-selective Rexinoids Suggests That the Peroxisome Proliferator-activated Receptor-Retinoid X Receptor Heterodimer Is Their Molecular Target*

J. Auwerx, P. Besnard, J. Fruchart, 2000, The Journal of Biological Chemistry.

Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5.

Len A Pennacchio, Bryan Brewer, L. Pennacchio, 2004, Biochemical and biophysical research communications.

Transcriptional Regulation of Apolipoprotein A5 Gene Expression by theNuclear Receptor ROR alpha

L. Pennacchio, D. Hum, B. Staels, 2004 .

PPAR-α and atherosclerosis from basic research to clinical applications

J. Fruchart, P. Duriez, 2004 .

Apolipoprotein A5 is an inflammatory responsive gene down-regulated by tumor necrosis factor alpha and interleukin-1

L. Pennacchio, E. Rubin, J. Fruchart, 2004 .

Jean-charles Fruchart Transcriptional Regulation of Apolipoprotein A5 Gene Expression by the Nuclear

L. Pennacchio, D. Hum, B. Staels, 2022 .

The Nuclear Receptors Peroxisome Proliferator-activated Receptor α and Rev-erbα Mediate the Species-specific Regulation of Apolipoprotein A-I Expression by Fibrates*

V. Laudet, B. Staels, J. Fruchart, 1998, The Journal of Biological Chemistry.

The orphan nuclear receptor RORα is a negative regulator of the inflammatory response

J. Mariani, D. Monté, B. Staels, 2001 .

Apolipoprotein A-V gene polymorphisms in subjects with metabolic syndrome

J. Fruchart, A. Sima, L. Niculescu, 2007, Clinical chemistry and laboratory medicine.

Circadian and Glucocorticoid Regulation of Rev-erbα Expression in Liver.

V. Laudet, B. Staels, F. Delaunay, 2000, Endocrinology.

[Metabolic study of 3 lipid emulsions used parenteral feedings. I. Exploration in vivo in the minipig].

J. Fruchart, A. Nouvelot, P. Dewailly, 1975, Nutrition and metabolism.

PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway.

M. Jaye, H. Brewer, A. Remaley, 2000, Nature medicine.

patients The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic

F. Sacks, P. Zimmet, C. Wanner, 2011 .

Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of Type 2 diabetes and atherosclerosis

B. Staels, J. Fruchart, C. Glineur, 2006, Expert opinion on emerging drugs.

Serum lipoprotein profile in Algerian patients with celiac disease.

J. Fruchart, V. Clavey, S. Médiène, 1995, Clinica chimica acta; international journal of clinical chemistry.

Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement.

F. Hu, R. Ross, J. Després, 2019, The lancet. Diabetes & endocrinology.

Genomic and non-genomic interactions of PPARα with xenobiotic-metabolizing enzymes

C. Fontaine, B. Staels, O. Barbier, 2004, Trends in Endocrinology & Metabolism.

Peroxisome Proliferator-activated Receptor α Induces Hepatic Expression of the Human Bile Acid Glucuronidating UDP-glucuronosyltransferase 2B4 Enzyme*

B. Staels, O. Barbier, J. Fruchart, 2003, Journal of Biological Chemistry.

The Farnesoid X Receptor Modulates Hepatic Carbohydrate Metabolism during the Fasting-Refeeding Transition*

Folkert Kuipers, A. Grefhorst, F. Gonzalez, 2005, Journal of Biological Chemistry.

Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III.

J. Fruchart, C. S. Wang, A. Tartar, 1992, Journal of lipid research.

The orphan nuclear receptor Rev-Erbalpha is a peroxisome proliferator-activated receptor (PPAR) gamma target gene and promotes PPARgamma-induced adipocyte differentiation.

S. Mandrup, F. Soncin, C. Fontaine, 2003, The Journal of biological chemistry.

Analysis of phospholipid transfer during HDL binding to platelets using a fluorescent analog of phosphatidylcholine.

G. Torpier, J. Fruchart, P. Duthilleul, 1987, Thrombosis research.

Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells.

N. Marx, B. Staels, J. Fruchart, 2004, Circulation research.

Therapeutic roles of peroxisome proliferator-activated receptor agonists.

B. Staels, J. Fruchart, 2005, Diabetes.

Peroxisome Proliferator–Activated Receptor α Improves Pancreatic Adaptation to Insulin Resistance in Obese Mice and Reduces Lipotoxicity in Human Islets

F. Pattou, J. Kerr-Conte, B. Staels, 2006, Diabetes.

Effects of unsaturated fatty acids in phospholipids on the in vitro activation of the lipoprotein lipase and the triglyceride lipase.

J. Fruchart, P. Dewailly, C. Desreumaux, 1979, Arzneimittel-Forschung.

Characterization of the Human PPAR Promoter : Identification of a Functional Nuclear Receptor Response Element

Y. Jamshidi, B. Staels, J. Fruchart, 2002 .

4-Mercaptoimidazoles derived from the naturally occurring antioxidant ovothiols 1. Antioxidant properties

F. Bailly, H. Vezin, J. Fruchart, 2000, Free radical research.

Peroxisome proliterator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis

B. Staels, J. Fruchart, P. Duriez, 1999 .

DNA polymorphisms of human apolipoprotein A‐IV gene: frequency and effects on lipid, lipoprotein and apolipoprotein levels in a French population

G. Siest, R. Guéguen, J. Fruchart, 1994, Clinical genetics.

Adrenocorticotrophic hormone lowers serum Lp(a) and LDL cholesterol concentrations in hemodialysis patients.

J. Dallongeville, P. Nilsson-ehle, J. Fruchart, 1997, Kidney international.

Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study.

A. Evans, D. Arveiler, G. Luc, 2002, Atherosclerosis.

Is lipoprotein(a) a clinically meaningful risk marker for cardiovascular events in healthy women?

J. Fruchart, 2007, Nature Clinical Practice Cardiovascular Medicine.

Inhibition enzyme immunoassay, application to human apolipoprotein B.

J. Fruchart, D. Bout, Y. Carlier, 1978, Journal of immunological methods.

Transcriptional Regulation of Human Rev-erbα Gene Expression by the Orphan Nuclear Receptor Retinoic Acid-related Orphan Receptor α*

D. Monté, E. Raspé, C. Fontaine, 2002, The Journal of Biological Chemistry.

Liver X Receptor Activation Potentiates the Lipopolysaccharide Response in Human Macrophages

A. Nohara, C. Fontaine, B. Staels, 2007, Circulation research.

Six DNA polymorphisms in the low density lipoprotein receptor gene: their genetic relationship and an example of their use for identifying affected relatives of patients with familial hypercholesterolaemia.

V. Gudnason, S. Humphries, J. Fruchart, 1993, Journal of medical genetics.

Phosphorylation-dependent down-regulation of apolipoprotein A5 by 1 insulin 2 3

M. Taskinen, E. Rubin, B. Staels, 2004 .

Apolipoprotein AII enrichment of HDL enhances their affinity for class B type I scavenger receptor but inhibits specific cholesteryl ester uptake.

J. Fruchart, O. Briand, V. Clavey, 2000, Arteriosclerosis, thrombosis, and vascular biology.

Scavenger Receptor but Inhibits Specific Cholesteryl Ester Uptake Apolipoprotein AII Enrichment of HDL Enhances Their Affinity for Class B Type I

J. Fruchart, O. Briand, V. Clavey, 2000 .

Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice.

J. Auwerx, E. Rubin, A. Guillouzo, 1996, The Journal of clinical investigation.

Apolipoprotein A-containing lipoprotein particles: physiological role, quantification, and clinical significance.

J. Fruchart, G. Ailhaud, 1992, Clinical chemistry.

Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors in Lipid Metabolism and Atherosclerosis

B. Staels, O. Barbier, J. Fruchart, 2002, Arteriosclerosis, thrombosis, and vascular biology.

PPARs and Atherosclerosis

B. Staels, J. Fruchart, I. Torra, 2000 .

Alterations in Lipoprotein Metabolism in Peroxisome Proliferator-activated Receptor α-deficient Mice*

J. Auwerx, J. Peters, F. Gonzalez, 1997, The Journal of Biological Chemistry.

Apolipoprotein A-I domains involved in the activation of lecithin:cholesterol acyltransferase. Importance of the central domain.

Y. Marcel, J. Fruchart, L. Calabresi, 1993, The Journal of biological chemistry.

Circadian and glucocorticoid regulation of Rev-erbalpha expression in liver.

V. Laudet, B. Staels, F. Delaunay, 2000, Endocrinology.

Peroxisome proliferator-activated receptors: new targets for the pharmacological modulation of macrophage gene expression and function

B. Staels, J. Fruchart, G. Chinetti, 2003, Current opinion in lipidology.

C-Reactive Protein, Interleukin-6, and Fibrinogen as Predictors of Coronary Heart Disease: The PRIME Study

A. Evans, D. Arveiler, G. Luc, 2003, Arteriosclerosis, thrombosis, and vascular biology.

Peroxisome Proliferator Activated Receptors: From Basic Science to Clinical Applications

A. Gotto, B. Staels, A. Catapano, 2002, Medical Science Symposia Series.

Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall

B. Staels, J. Fruchart, G. Chinetti, 2001, Zeitschrift für Kardiologie.

Characterization of a new mouse model for human apolipoprotein A-I/C-III/A-IV deficiency Published, JLR Papers in Press, February 23, 2006.

N. Maeda, G. Torpier, J. Fruchart, 2006, Journal of Lipid Research.

Two regulatory elements of similar structure and placed in tandem account for the repressive activity of the first intron of the human apolipoprotein A-II gene.

J. Auwerx, B. Staels, B. Laine, 1996, The Biochemical journal.

Regulation of Human ApoA-I by Gemfibrozil and Fenofibrate Through Selective Peroxisome Proliferator–Activated Receptor &agr; Modulation

G. Luc, J. Peters, F. Gonzalez, 2005, Arteriosclerosis, thrombosis, and vascular biology.

Human free apolipoprotein A-I and artificial pre-beta-high-density lipoprotein inhibit eNOS activity and NO release.

R. Bordet, G. Torpier, J. Fruchart, 2004, Biochimica et biophysica acta.

A 700-bp fragment of the human antithrombin III promoter is sufficient to confer high, tissue-specific expression on human apolipoprotein A-II in transgenic mice.

N. Duchange, D. Branellec, J. Fruchart, 1995, Gene.

Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor.

B. Staels, J. Fruchart, C. Duval, 2003, Molecular endocrinology.

In vivo metabolism of apolipoprotein A-I on high density lipoprotein particles LpA-I and LpA-I,A-II.

D. Rader, H. Brewer, J. Fruchart, 1991, Journal of lipid research.

CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors.

A. Tedgui, B. Staels, J. Fruchart, 2000, Circulation.

Novel QTLs for HDL levels identified in mice by controlling for Apoa2 allelic effects: confirmation of a chromosome 6 locus in a congenic strain.

A. Lusis, M. Mehrabian, P. Wen, 2004, Physiological genomics.

Negative Regulation of Human Fibrinogen Gene Expression by Peroxisome Proliferator-activated Receptor α Agonists via Inhibition of CCAAT Box/Enhancer-binding Protein β*

Robert Kleemann, Teake Kooistra, T. Kooistra, 2001, The Journal of Biological Chemistry.

Cloning and sequencing of cDNAs encoding the human hepatocyte nuclear factor 4 indicate the presence of two isoforms in human liver.

V. Laudet, B. Laine, J. Fruchart, 1994, Gene.

Extracellular Human Thioredoxin-1 Inhibits Lipopolysaccharide-induced Interleukin-1β Expression in Human Monocyte-derived Macrophages*

K. Brand, L. Billiet, J. Fruchart, 2005, Journal of Biological Chemistry.

Thioredoxin reductase 1 is upregulated in atherosclerotic plaques: specific induction of the promoter in human macrophages by oxidized low-density lipoproteins.

M. Jaye, Elias S. J. Arnér, J. Fruchart, 2004, Free radical biology & medicine.

Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content

H. Aburatani, M. Anai, J. Fruchart, 2020, Scientific Reports.

[Erucic acid metabolism in man and animals: myocardial extraction in man after an overload of rapeseed oil and tissue lipids in the rat after an overload of trierucin].

J. Fruchart, P. Dewailly, J. Jaillard, 1973, Nutrition and metabolism.

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.

N. Paynter, P. Ridker, J. Buring, 2022, The New England journal of medicine.

Plasma cholesterol and endogenous cholesterol synthesis during refeeding in anorexia nervosa.

J. Fruchart, C. Feillet-Coudray, J. Bard, 2000, Clinica chimica acta; international journal of clinical chemistry.

Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty.

A. Castaigne, J. Cassagnes, E. Belle, 1997, Journal of the American College of Cardiology.

Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes

J. Hsia, S. Grundy, P. Barter, 2006, Diabetes Care.

Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group.

A. Gotto, A. Keech, S. Grundy, 1998, The American journal of cardiology.

Different ways to regulate the PPARα stability

B. Staels, J. Fruchart, C. Blanquart, 2004 .

HDL3 binds to glycosylphosphatidylinositol-anchored proteins to activate signalling pathways.

P. Denéfle, D. Rouy, J. Fruchart, 1997, Biochimica et biophysica acta.

Acute Antiinflammatory Properties of Statins Involve Peroxisome Proliferator–Activated Receptor-α via Inhibition of the Protein Kinase C Signaling Pathway

D. Dombrowicz, B. Staels, O. Barbier, 2006, Circulation research.

Lipoproteins, apolipoproteins and coronary artery disease

J. Fruchart, V. Clavey, M. Bertrand, 1982, La Ricerca in clinica e in laboratorio.

Alterations in the main steps of reverse cholesterol transport in male patients with primary hypertriglyceridemia and low HDL-cholesterol levels.

J. Fruchart, F. Brites, B. Delfly, 2000, Atherosclerosis.

VLDL compositional changes and plasma levels of triglycerides and high density lipoprotein.

J. Fruchart, F. Brites, G. Castro, 1998, Clinica chimica acta; international journal of clinical chemistry.

Plasma apolipoprotein A-I, A-II, B, E and C-III containing particles in men with premature coronary artery disease.

J. Ordovás, P. Wilson, E. Schaefer, 1991, Atherosclerosis.

Increased ABCA1 activity protects against atherosclerosis.

B. McManus, M. Hayden, B. Staels, 2002, The Journal of clinical investigation.

Peroxisome proliferator-activated receptor-α activation and high-density lipoprotein metabolism☆

J. Fruchart, 2001 .

Lipoprotein Particles Heterogeneity: Clinical and Pharmacological Implication

J. Fruchart, 1993 .

This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted PDF and full text (HTML) versions will be made available soon.

G. Assmann, J. Fruchart, H. Ginsberg, 2014 .

Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression.

F. Gonzalez, Y. Inoue, B. Staels, 2003, Gastroenterology.

Is cholesterol the major lipoprotein risk factor in coronary heart disease?--a Franco-Scottish overview.

C. Packard, J. Fruchart, C. J. Packard, 1997, Current medical research and opinion.

PPARα Agonists Inhibit Tissue Factor Expression in Human Monocytes and Macrophages

B. Jude, B. Staels, J. Fruchart, 2001 .

Liver X receptors and the control of cholesterol homeostasis: potential therapeutic targets for the treatment of atherosclerosis.

B. Staels, J. Fruchart, L. Millatt, 2003, Biochimica et biophysica acta.

Enzyme-linked immunosorbent assay for human proapolipoprotein A-I using specific antibodies against synthetic peptide.

J. Fruchart, A. Tartar, A. Barkia, 1988, Journal of lipid research.

Adipophilin Enhances Lipid Accumulation and Prevents Lipid Efflux From THP-1 Macrophages: Potential Role in Atherogenesis

M. Jaye, J. Fruchart, M. Rouis, 2004, Arteriosclerosis, thrombosis, and vascular biology.

SPPARM alpha: the Lazarus effect.

R. Santos, J. Fruchart, 2019, Current opinion in lipidology.

Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Témoins sur 'Infarctus du Myocarde.

D. Arveiler, G. Luc, F. Cambien, 1996, Journal of lipid research.

Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and incident coronary heart disease: the PRIME Study.

A. Evans, D. Arveiler, G. Luc, 2003, Atherosclerosis.

Implications of the ACCORD Lipid study: perspective from the Residual Risk Reduction Initiative (R3i)

F. Sacks, J. Fruchart, M. Hermans, 2010, Current medical research and opinion.

Early-glycation of apolipoprotein E: effect on its binding to LDL receptor, scavenger receptor A and heparan sulfates.

G. Siest, N. Taniguchi, J. Fruchart, 2002, Biochimica et biophysica acta.

Review: Vascular protective effects of peroxisome proliferator-activated receptor agonists

B. Staels, J. Fruchart, B. Cariou, 2005 .

Coronary heart disease: reducing the risk: a worldwide view. International Task Force for the Prevention of Coronary Heart Disease.

G. Assmann, P. Cullen, F. Jossa, 1999, Circulation.

Commentary Implications of the ACCORD Lipid study: perspective from the Residual Risk Reduction

J. Fruchart, 2010 .

Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway.

B. Staels, J. Fruchart, G. Chinetti, 1999, Circulation research.

1.P.395 Measurements of VLDL-, IDL-, and LDL-apo B levels by a combination of isopropanol precipitation and mass spectrometry

G. Luc, N. Duhal, L. Béghin, 1997 .

Coronary heart disease: reducing the risk: a worldwide view. International Task Force for the Prevention of Coronary Heart Disease.

G. Assmann, P. Cullen, F. Jossa, 1999, Circulation.

Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non-Alcoholic Steatohepatitis

H. Aburatani, T. Kodama, M. Anai, 2022, Cells.

Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists

J. Fruchart, Jean-Charles Fruchart, 2013, Cardiovascular Diabetology.

Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial.

S. Yamashita, T. Kodama, H. Arai, 2016, Atherosclerosis.

Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians

J. Fruchart, M. Hermans, 2011, Therapeutic advances in chronic disease.

Reducing residual vascular risk in patients with atherogenic dyslipidemia: where do we go from here?

J. Fruchart, M. Hermans, 2010 .

The nuclear receptor Rev-erbalpha is a liver X receptor (LXR) target gene driving a negative feedback loop on select LXR-induced pathways in human macrophages.

C. Fontaine, B. Staels, J. Fruchart, 2008, Molecular endocrinology.

nzyme-Linked ImmunosorbentAssay for Serum Amyloid A Apolipoproteinwith Use of Specific ntibodiesagainst Synthetic Peptides

G. Hocke, J. Fruchart, A. Tartar, 1988 .

Immunochemical determination of human apolipoprotein B by laser nephelometry.

J. Fruchart, P. Dewailly, G. Sezille, 1979, Clinica chimica acta; international journal of clinical chemistry.

Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content

H. Aburatani, T. Kodama, M. Anai, 2020, Scientific Reports.

Peroxisome proliferator-activated receptor-alpha activation and high-density lipoprotein metabolism.

J. Fruchart, 2001, The American journal of cardiology.

Antipeptide antibodies discriminate between different SAA proteins in human plasma.

G. Hocke, J. Fruchart, A. Tartar, 1989, Biochimica et biophysica acta.

Enzyme-linked immunosorbent assay for serum amyloid A apolipoprotein with use of specific antibodies against synthetic peptides.

G. Hocke, J. Fruchart, A. Tartar, 1988, Clinical chemistry.

Antiatherogenic Effect of Apolipoprotein A-I Containing Lipoproteins

J. Fruchart, A. Barkia, R. Barbaras, 1989 .

Complete functional rescue of the ABCA1−/− mouse by human BAC transgenesis Published, JLR Papers in Press, March 16, 2005. DOI 10.1194/jlr.M400506-JLR200

David J. Arenillas, M. Hayden, W. Wasserman, 2005, Journal of Lipid Research.

Implications of emerging risk factors for therapeutic intervention.

A. von Eckardstein, G. Assmann, P. Cullen, 2005, Nutrition, metabolism, and cardiovascular diseases : NMCD.

Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramine

J. Fruchart, H. Eriksen, J. Bard, 2004, European Journal of Clinical Pharmacology.

Adipose tissue lipoprotein lipase activity in Plasmodium chabaudi and Plasmodium vinckei rodent malaria.

J. Fruchart, P. Charet, P. Maurois, 1982, Biochimie.

Clinical Significance of Lipoprotein Particles

J. Fruchart, C. Fiévet, P. Duriez, 1989 .

Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

A. Gotto, S. Grundy, P. Barter, 2005, New England Journal of Medicine.

Plasma cystatin-C and development of coronary heart disease: The PRIME Study.

A. Evans, D. Arveiler, G. Luc, 2006, Atherosclerosis.

Fish eye disease: structural and metabolic abnormalities of high density lipoproteins

G. Luc, N. Duhal, J. Fruchart, 1994 .

PPARS, metabolic disease and atherosclerosis.

B. Staels, J. Fruchart, P. Duriez, 2001, Pharmacological research.

Role of Lp A-I and Lp A-I/A-II in cholesteryl ester transfer protein-mediated neutral lipid transfer. Studies in normal subjects and in hypertriglyceridemic patients before and after fenofibrate therapy.

Y. Marcel, R. McPherson, J. Fruchart, 1996, Arteriosclerosis, thrombosis, and vascular biology.

Polymorphisms of the apolipoprotein B and E genes and their relationship to plasma lipid variables in healthy Chinese men

L. Tiret, F. Cambien, J. Fruchart, 1993, Human Genetics.

Phosphatidylcholine breakdown in HDL3 stimulated platelets.

J. Fruchart, H. Nazih, F. Martin-Nizard, 1990, Thrombosis research.

Structural domain of apolipoprotein A-I involved in its interaction with cells.

P. Duchateau, R. Brasseur, P. Denéfle, 1994, Biochimica et biophysica acta.

Expression in Vascular Cells Peroxisome Proliferator-Activated Receptors and Atherogenesis : Regulators of Gene

N. Marx, B. Staels, J. Fruchart, 2004 .

This Review Is Part of a Thematic Series on Nuclear Receptor Signaling, Which Includes the following Articles: Peroxisome Proliferator-activated Receptors and Atherogenesis: Regulators of Gene Expression in Vascular Cells Nuclear Receptor Signaling in the Control of Cholesterol Homeostasis Nuclear R

N. Marx, B. Staels, D. Kelly, 2022 .

Kinetic study of serum lipoproteins, total cholesterol and triacylglycerides in various models of experimental rodent malaria.

J. Fruchart, A. Nouvelot, P. Charet, 1980, Annals of tropical medicine and parasitology.

Effect of fenofibrate treatment on type III hyperlipoproteinemia.

J. Fruchart, C. Fiévet, J. Davignon, 1987, The American journal of medicine.

Synthetic peptides as alternative antigens in the production of antibodies against human apolipoproteins.

J. Fruchart, A. Tartar, J. Gesquiere, 1985, Clinical chemistry.

An InternationalCollaborativeStudyon Standardizationof ApolipoproteinsA-I and B. Part I. Evaluationof a LyophilizedCandidateReferenceand CalibrationMaterial1

G. Cooper, G. Schonfeld, E. Stein, 1987 .

Cigarette smoking is associated with differences in nutritional habits and related to lipoprotein alterations independently of food and alcohol intake.

P. Amouyel, J. Dallongeville, M. Fantino, 1996, European Journal of Clinical Nutrition.

Hepatic Expression of the UGT1A9 Gene Is Governed by Hepatocyte Nuclear Factor 4α

C. Guillemette, F. Gonzalez, Y. Inoue, 2005, Molecular Pharmacology.

EUROSTERONE MEETING Peroxisome proliferator-activated receptors in inflammation control

B. Staels, J. Fruchart, P. Delerive, 2001 .

Glucose regulates LXRalpha subcellular localization and function in rat pancreatic beta-cells.

C. Sergheraert, F. Pattou, J. Fruchart, 2006, Cell Research.

Logistic discriminant analysis of lipids and apolipoproteins in a population of coronary bypass patients and the significance of apolipoproteins C-III and E.

J. Fruchart, J. Bard, J. Auget, 1990, Atherosclerosis.

Quantitative determination of different apolipoprotein B containing lipoproteins by an enzyme linked immunosorbent assay: apo B with apo C-III and apo B with apo E.

J. Fruchart, J. Bard, A. Kandoussi, 1991, Journal of immunoassay.

Quantitative abnormalities of lipoprotein particles in chronic hemodialysis patients.

J. Fruchart, H. Parra, A. Tacquet, 1988, Advances in experimental medicine and biology.

Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.

Fulvio Loiodice, Vincenzo Tortorella, Ettore Novellino, 2005, Journal of medicinal chemistry.

Coadministration of ezetimibe and fenofibrate leads to favorable effects on Apo CIII and LDL subfractions

J. Fruchart, M. Guillaume, M. Affrime, 2001 .

Rapid sodium dodecyl sulfat/polyacrylamide gel electrophoresis of urinary proteins.

J. Fruchart, A. Tacquet, C. Mizon, 1980, Clinical chemistry.

PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages.

B. Jude, B. Staels, J. Fruchart, 2001, Circulation.

Developmental and pharmacological regulation of apolipoprotein C-II gene expression. Comparison with apo C-I and apo C-III gene regulation.

A. V. Sechkin, B. Staels, J. Fruchart, 1999, Arteriosclerosis, thrombosis, and vascular biology.

Changes in plasmaapolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine

J. Dallongeville, J. Fruchart, P. Duriez, 1995 .

Mechanism of lipid lowering in mice expressing human apolipoprotein A5

E. Rubin, B. Brewer, J. Fruchart, 2005 .

Branched synthetic constructs that mimic the physico-chemical properties of apolipoprotein AI in reconstituted high-density lipoproteins.

M. Rosseneu, B. Vanloo, J. Fruchart, 1996, European journal of biochemistry.

Fluvastatin reduces levels of plasma apo B-containing particles and increases those of LpA-I. European Fluvastatin Study Group.

J. Dallongeville, J. Fruchart, J. Bard, 1994, The American journal of medicine.

DNA binding-independent induction of IkappaBalpha gene transcription by PPARalpha.

G. Haegeman, K. De Bosscher, B. Staels, 2002, Molecular endocrinology.

Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta.

B Staels, T. Kooistra, R. Kleemann, 2001, The Journal of biological chemistry.

[Anti-cholesterol agents, new therapeutic approaches].

J. Fruchart, P. Duriez, 2004, Annales Pharmaceutiques Françaises.

Pharmacodynamic and pharmaco-kinetic interaction between fenofibrate and ezetimibe*

J. Fruchart, M. Guillaume, D. Cutler, 2004, Current medical research and opinion.

PPARα, Lipoprotein Metabolism, Metabolic Diseases, and Atherosclerosis

B. Staels, J. Fruchart, P. Duriez, 2002 .

Double-Blind Comparison of Apolipoprotein and Lipoprotein Particle Lowering Effects of Atorvastatin and Pravastatin Monotherapy in Patients With Primary Hypercholesterolemia

C. Sirtori, J. Dallongeville, J. Fruchart, 1998, Journal of cardiovascular pharmacology and therapeutics.

Mechanisms of the hypolipidemic action of fibrates

J. Auwerx, J. Dallongeville, B. Staels, 1998 .

Accessibility of human apolipoprotein B-100 epitopes in insulin-dependent diabetes: relation with the surface lipid environment of atherogenic particles.

J. Fruchart, P. Drouin, C. Fiévet, 1996, Diabetes & metabolism.

PPAR alpha, fibrates, lipid metabolism and inflammation.

B. Staels, J. Fruchart, C. Duval, 2004, Archives des maladies du coeur et des vaisseaux.

Dosage semi-automatique de l'activité lipolytique du plasma post-héparine. Bilan des premiéres applications cliniques

J. Fruchart, P. Scherpereel, J. Jaillard, 1972 .

Oxidized phospholipids activate PPARα in a phospholipase A2‐dependent manner

B. Staels, J. Fruchart, P. Delerive, 2000 .

Transcriptional regulation of human Rev-erbalpha gene expression by the orphan nuclear receptor retinoic acid-related orphan receptor alpha.

D. Monté, E. Raspé, C. Fontaine, 2002, The Journal of biological chemistry.

[Effect of alcohol on removal of lipids from plasma after hyperlipemic induced by a fatty meal or perfusion of lipid emulsions in man].

J. Fruchart, P. Scherpereel, P. Dewailly, 1973, Nutrition and Metabolism.

Native like structure and stability of apo AI in a n‐propanol/water solution as determined by 13C NMR

J. Wieruszeski, G. Lippens, J. Fruchart, 1995, FEBS letters.

Apolipoprotein E-∈A allele and Alzheimer's disease

G. Siest, C. Masters, S. Lovestone, 1993, The Lancet.

Use of synthetic peptides for specific assays of proproteins: Assay of proapolipoprotein A-I

J. Fruchart, A. Tartar, A. Barkia, 1988 .

Apolipoproteins in human amniotic fluid: concentrations, isoforms and polymorphism.

J. Fruchart, J. Bard, A. Barkia, 1989, Gynecologic and Obstetric Investigation.

Parental history of early myocardial infarction is associated with decreased levels of lipoparticle AI in adolescents.

P. Amouyel, J. Fruchart, J. Bard, 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

of lipoparticle AI in adolescents Parental history of early myocardial infarction is associated with decreased levels

P. Amouyel, J. Fruchart, J. Bard, 2011 .

Glucocorticoids induce the expression of the leptin gene through a non-classical mechanism of transcriptional activation.

J. Auwerx, J. Fruchart, P. Vos, 1998, European journal of biochemistry.

Characterization of Lipoprotein Particles Containing Apolipoprotein A-IV

P. Duchateau, J. Fruchart, G. Castro, 1993 .

Lipid Free Apolipoprotein E Binds to the Class B Type I Scavenger Receptor I (SR-BI) and Enhances Cholesteryl Ester Uptake from Lipoproteins*

G. Siest, J. Fruchart, A. Tailleux, 2002, The Journal of Biological Chemistry.

Beneficial effects of fibrates on apolipoprotein A-I metabolism occur independently of any peroxisome proliferative response.

L. Madsen, R. Berge, B. Staels, 1999, Circulation.

Lipoprotein metabolism in marasmic children of northern Mauritania.

J. Fruchart, J. Bard, F. Feillet, 1993, The American journal of clinical nutrition.

Effects of different dietary cholesterol concentrations on lipoprotein plasma concentrations and on cholesterol efflux from Fu5AH cells.

J. López-Miranda, J. Fruchart, F. Perez-Jimenez, 1998, The American journal of clinical nutrition.

Fenofibrate increases homocystinemia through a PPARalpha-mediated mechanism.

G. Luc, P. Giral, B. Staels, 2004, Journal of Cardiovascular Pharmacology.

Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region.

M. Rossor, A. Delacourte, A. Evans, 1994, Human molecular genetics.

Determination of amniotic fluid phospholipids by thin-layer chromatography, with use of a hydrogen flame ionization detector.

J. Fruchart, N. Porchet, X. Codaccioni, 1979, Clinical chemistry.

Accumulation of Triglyceride-Rich Lipoprotein in Subjects With Abdominal Obesity: The Biguanides and the Prevention of the Risk of Obesity (BIGPRO) 1 Study

M. Safar, M. Charles, J. Fruchart, 2001, Arteriosclerosis, thrombosis, and vascular biology.

Electroimmunoassay for determination of ApoB in human sera by using a mixture of monoclonal antibodies.

J. Fruchart, C. Fiévet, S. Goldstein, 1987, Clinical chemistry.

Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates.

J. Auwerx, J. Dallongeville, B. Staels, 1995, The Journal of clinical investigation.

Human apolipoprotein A-IV binds to apolipoprotein A-I/A-II receptor sites and promotes cholesterol efflux from adipose cells.

J. Fruchart, V. Clavey, R. Barbaras, 1990, The Journal of biological chemistry.

Different VLDL apo B, and HDL apo AI and apo AII metabolism in two heterozygous carriers of unrelated mutations in the lipoprotein lipase gene.

G. Luc, N. Duhal, J. Bonte, 2006, Clinica chimica acta; international journal of clinical chemistry.

diabetes RECORD : Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes ACCORD : Action to Control Cardiovascular Risk in diabetes ACT NOW : Act Now for the Prevention of Type 2 Diabetes

B. Staels, J. Fruchart, H. Duez, 2004 .

Di‐tert‐butylhydroxylated flavonoids protect endothelial cells against oxidized LDL‐induced cytotoxicity

J. Fruchart, P. Duriez, N. Cotelle, 2001, Journal of biochemical and molecular toxicology.

The blood-brain barrier in vitro : co-culture of brain capillary endothelial cells and astrocytes

M. Dehouck, R. Cecchelli, S. Méresse, 1990 .

Novel peroxisome proliferator activated receptor-alpha agonists.

J. Fruchart, 2007, The American journal of cardiology.

[New methods in lipid research].

G. Luc, J. Fruchart, 1994, Presse medicale.

PPAR activators improve glucose homeostasis by changing fatty acid partitioning

J. Auwerx, K. Schoonjans, B. Staels, 1998 .

Upregulation of the low density lipoprotein receptor at the blood-brain barrier: intercommunications between brain capillary endothelial cells and astrocytes

M. Dehouck, R. Cecchelli, J. Fruchart, 1987, The Journal of cell biology.

Preformed PAF‐acether and lyso PAF‐acether are bound to blood lipoproteins

J. Fruchart, J. Benveniste, P. Duriez, 1988, FEBS letters.

Molecular analysis of atherogenic lipoprotein particles in adequately controlled type I diabetes mellitus.

J. Fruchart, P. Drouin, C. Fiévet, 1988, Advances in experimental medicine and biology.

Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III.

J. Fruchart, A. Tartar, J. Gesquiere, 1992, Journal of lipid research.

Cell Culture Conditions Determine Apolipoprotein CIII Secretion and Regulation by Fibrates in Human Hepatoma HepG2 Cells

J. Dallongeville, B. Staels, J. Fruchart, 1999, Cellular Physiology and Biochemistry.

Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia.

G. Jackson, G. Mcinnes, M. Mir, 1994, The American journal of medicine.

Tissue-Specific Roles of ABCA1 Influence Susceptibility to Atherosclerosis

B. McManus, M. Hayden, J. Parks, 2009, Arteriosclerosis, thrombosis, and vascular biology.

Aspects of cholesterol metabolism in normal and hypercholesterolemic Syrian hamsters. Influence of fenofibrate.

J. Fruchart, V. Clavey, D. Marzin, 1988, Methods and findings in experimental and clinical pharmacology.

Phosphorylation-dependent down-regulation of apolipoprotein A5 by insulin

L. Pennacchio, M. Taskinen, E. Rubin, 2004 .

Mapping of lipoprotein particles with monoclonal antibodies in diabetes and atherosclerosis.

J. Fruchart, P. Fiévet, P. Drouin, 1985, Monographs on atherosclerosis.

Molecular analysis of lipoproteins: clinical applications.

J. Fruchart, C. Fiévet, J. Gesquiere, 1987, Advances in experimental medicine and biology.

Residual Microvascular Risk in Type 2 Diabetes in 2014: Is it Time for a Re-Think? A Perspective from the Residual Risk Reduction Initiative (R3i)

P. Amarenco, J. Fruchart, K. Al-Rubeaan, 2014 .

Evaluation of apolipoprotein A-I containing particles in chronic renal failure patients undergoing hemodialysis.

J. Fruchart, A. Kandoussi, A. Tacquet, 1990, American journal of nephrology.

Atheroprotective Effect of Human Apolipoprotein A5 in a Mouse Model of Mixed Dyslipidemia

B. Staels, J. Fruchart, C. Fiévet, 2008, Circulation research.

Low-density lipoprotein for delivery of an acrylophenone antineoplastic molecule into malignant cells.

D. Lesieur, G. Favre, J. Fruchart, 1992, Cancer research.

Oxidized phospholipids activate PPARα in a phospholipase A2-dependent manner

B. Staels, J. Fruchart, P. Delerive, 2000 .